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1 Introduction 
 
Transplantation of solid organs is a frequent procedure in modern medicine and 
represents the therapy of choice for end-stage organ failure. Transplantation 
between genetically different individuals induces a rapid and destructive 
immune response, which, in the absence of immunosuppression, leads to graft 
destruction. This type of immune response, called rejection, is primarily driven 
by the ability of alloreactive host T cells to recognize the polymorphism encoded 
within the molecules of the major histocompatibility complex or MHC.  
 
Major improvements in surgical techniques, MHC matching and immuno-
suppressive drugs have increased the one-year survival rate for most solid 
organ grafts to over 90% (Hariharan S et al., 2000). The success of clinical 
transplantation depends largely on the successful suppression of rejection. 
Although different immunosuppressive drugs found access into the clinic in the 
past two decades, most of them cause severe side-effects. Drug-related 
adverse effects (nephrotoxicity, diabetes and hyperlipidaemia) and a reduced 
immunity to infections and malignant diseases are caused by the life-long 
immunosuppression required to minimize the risk of allograft rejection (Dowling 
JN et al., 1976). However, an alternative to the immunosuppression does not 
exist presently in the clinic.  
 
The experimental transplantation immunology searches for alternatives to the 
life-long immunosuppression (Strober S et al., 2000). Strategies for the sup-
pression of the allograft rejection in an antigen-specific manner are preferred 
(Fändrich F et al., 2004). This would help to inhibit only the unwanted immune 
responses directed towards the transplant and maintain the beneficial immune 
responses towards infections and malignancies. The great perspective is that 
the patients will be independent of life-long immunosuppression. Dendritic cells, 
the most important antigen-presenting cells of the immune system which initiate 
and regulate immune responses, can be of great importance for tolerogenic 
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strategies after transplantation due to their ability to induce antigen-specific 
unresponsiveness (Banchereau J et al., 2000; Coates PT et al., 2002).  
 
1.1 An overview of allorecognition and graft rejection 
The reason for allograft rejection is that the immune system of the recipient is 
activated by allogeneic MHC molecules expressed on the allograft. Alloreactive 
T cells recognize the differences in the MHC molecules between donor and 
recipient and induce a complex immune response which includes all 
components of the innate and adaptive immune system. The capital importance 
of alloreactive T cells in this process was demonstrated in different T cell-
deficient animal models (Rosenberg AS and Singer A, 1992). Alloreactive T 
cells recognize allogeneic MHC antigens via two distinct mechanisms (Rogers 
NJ and Lechler RI, 2001): the direct pathway and the indirect pathway of 
allorecognition (Figure 1.1).  
 
The direct pathway of allorecognition 
The direct recognition of allogeneic MHC class I and class II molecules on the 
surface of donor-derived, so-called passenger leukocytes, by host T cells 
results in the generation of cytotoxic and helper T cells (Lechler R and 
Batchelor JR, 1982). These passenger leukocytes are transferred together with 
the transplanted organ into the recipient where some of them, for example 
dendritic cells, act as professional antigen-presenting cells. In the case of 
allogeneic transplantation (transplantation between non-identical individuals) all 
these cells express MHC molecules which are foreign or allogeneic to the 
recipient's immune cells.  
 
The importance of donor-derived dendritic cells for the direct activation of 
alloreactive T cells was demonstrated by different experiments, where their 
selective depletion increased allograft survival (Game DS and Lechler RI, 
2002). The molecular reason for the direct recognition of allogeneic MHC 
molecules is interpreted as a cross-reaction of certain subtypes of T cell 
receptors. These receptors, specific for a certain combination of self-MHC and 
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peptide, also recognize allogeneic MHC molecules (Shirwan H et al., 1995). 
Recent structural analysis of an alloreactive T cell receptor confirmed that it 
interacts with an allogeneic MHC/peptide complex in a mode similar to its 
interaction with self-MHC molecules (Reiser JB et al., 2000). The conesquence 
of an allogeneic situation, where both presented peptides and presenting MHC 
molecules are foreign, is that all MHC/peptide combinations on the surface of a 
donor-derived dendritic cell (more than 105 molecules) are potential targets for 
alloreactive T cells independent of the presented peptide. Between 0.1% and 
10% of an individual's T cell repertoire are capable of directly recognising 
allgeneic MHC molecules (Suchin EJ et al., 2001). This is a very high 
percentage when compared to the less than 0.001% of T cells responding to a 
"normal" non-allogeneic peptide (Karulin AY et al., 2000). The very high 
frequency of alloreactive T cells appears to be one reason for the extraordinary 
strength of the polyclonal alloimmune response mediated via the direct pathway 
of allorecognition.  
 
The indirect pathway of allorecognition 
In the indirect pathway of allorecognition, allogeneic MHC molecules are 
recognized as conventional peptide antigens by alloreactive T cells (Figure 1.1). 
This pathway became the focus of research early in the 1980s and it was 
shown to be the results of self-MHC-restricted presentation of donor MHC 
peptides. These peptides are processed and presented by antigen-presenting 
cells of the recipient, mainly by dendritic cells. The percentage of alloreactive T 
cells primed by the indirect pathway of allorecognition is about 100 times lower 
than that of T cells participating in the direct pathway (Liu Z et al., 1993; 
Benichou G, 1999). Although the number of responder T cells is much lower 
than in the direct allorecognition, this pathway is very important for the process 
of allograft rejection. It was clearly shown that the antigen recognition through 
this pathway induces allograft rejection (Auchincloss H et al., 1993; Preston EH 
et al., 2003). Recent studies have demonstrated that this pathway is implicated 
in the chronic rejection of transplanted organs (Shoskes DA and Wood KJ, 
1994). 
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Figure 1.1: Characteristics of the alloimmune response induced by the allograft in local 
lymph nodes. (a) Host T cells can be activated in response to an allogeneic stimulus by the 
direct or indirect allorecognition. In the direct pathway, alloreactive host T cells recognize intact 
donor MHC molecules on the surface of donor-derived passenger leukocytes (antigen-
presenting cells or APC). (b) In the indirect pathway, host T cells respond to processed donor-
derived allogeneic peptides bound to syngeneic or self-MHC molecules. (c) Particularly CD4+ T 
cells activate different cells of the innate and adoptive immune system over cytokines (d) which 
participate in graft rejection (e). 
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The indirect pathway occurs after transplantation when host antigen-presenting 
cells (mainly dendritic cells), which permanently guard the environment, take up 
and process allogeneic molecules shed from donor tissue. The phagocytosis of 
these molecules by host dendritic cells results in the presentation of allo-
peptides by self-MHC class II molecules. This leads to the activation of CD4+ T 
cells, in contrast to the direct pathway where both CD4+ and CD8+ T cells are 
activated (Popov IA et al., 1995; Benichou G, 1999). While the direct pathway 
depends on the limited presence of passenger leukocytes, the indirect pathway 
depends on the continuous supply of alloantigens from the graft. The activated 
CD4+ T cells provide further help for the activation of other effector cells such 
as B cells, natural killer cells and macrophages and together they lead to the 
allograft rejection (Figure 1.1).  
 
Ways of influencing allograft rejection 
The immunologic characteristics of the direct and indirect pathway may require 
individual strategies for immunosuppression. The direct pathway starting 
immediately after transplantation has to be controlled with a short-term immuno-
suppression because of its extraordinary strength. Most of the passenger 
leukocytes, responsible for this pathway, will be destroyed by the immune 
system and therefore, this pathway seems to be time-limited. An experimental 
validation of the fact that their selective depletion reduces the graft's 
immunogenicity and prolongs graft survival was given by Laferty's group 
(Talmage DW et al., 1976). However, this strategy alone will not induce long-
term allograft survival because firstly, the indirect pathway of allorecognition will 
not be influenced (Figure 1.1) and secondly, the direct alloreactivity may not 
necessarily be limited to the early phase of the allograft response. Donor 
endothelial cells express many of the same costimulatory and adhesion 
molecules found on dendritic cells to activate directly recipient CD8+ T cells 
(Kreisel D et al., 2002). In addition, the expression levels of MHC class I on 
donor endothelium are markedly up-regulated during allograft rejection. 
 
 6 
The indirect pathway of allorecognition is a chronic process which remains 
active as long as the transplanted organ is kept in the recipient. Through this 
pathway alloreactive T cells recognize the allogeneic MHC molecules as 
conventional peptide antigens bound by self-MHC class II molecules. Therefore, 
it may be possible to influence specifically alloreactive T cells activated by this 
pathway with distinct type of peptides with subtle modifications in their 
sequence, termed altered peptide ligands (Sloan-Lancaster J and Allen PM, 
1996). Altered peptide ligands have been studied in different murine models of 
autoimmune diseases because the dominant antigens are well characterized in 
most autoimmune diseases. Their use has highlighted the possibility of inducing 
a variety of biological activities, such as changes in the cytokine profile and 
induction of anergy (Sloan-Lancaster J et al., 1993). Although the use of altered 
peptide ligands has been well studied in experimental autoimmune diseases, 
very few data are yet available on the application of altered peptide ligands in 
transplantation. Present data show that such peptides can indeed inhibit the 
activation of alloreactive T cells in vitro by the indirect pathway of allorecognition 
(Frasca L et al., 2000; Sitaru AG et al., 2004). 
 
In general, T cell-mediated immunity occurs if T cells encounter their specific 
antigen in the restricted form of a peptide/self-MHC complex on the surface of 
antigen-presenting cells. Since the donor MHC peptides are the principal 
antigens in the initiation and maintenance of the alloimmune response, it is not 
surprising that most of the experimental studies have focused on modulation of 
the alloimmune response using MHC allopeptides (Sayegh MH et al., 1992). 
Some allopeptides have been shown to have potential immunomodulatory 
capacities when administrated intrathymically (Oluwole SF et al., 1993), orally 
(Zavazava N et al., 2000), or as peptide-pulsed recipient dendritic cells 
(Oluwole OO et al., 2001; Ali A et al., 2001). This demonstrates that allogeneic 
peptides are able to influence the T cell population by mechanisms belonging to 
the central and peripheral tolerance. Presently, components of the peripheral 
tolerance, including tolerogenic dendritic cells (Hackstein H and Thomson AW, 
2004) or regulatory T cells (Shevach EM, 2000), are preferred in order to 
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suppress the alloimmune response. With these cell subpopulations, the control 
of the alloimmune response is possible via the indirect pathway of allorecog-
nition but they can also address the direct pathway. Some studies showed 
indeed that the control of the indirect pathway also enables the control of the 
direct pathway (Cote I et al., 2001). 
 
 
1.2 The control of T cell activation by dendritic cells: immunity versus 
tolerance 
In 1973, Ralph M. Steinman and Zanvil A. Cohn identified a novel cell type in 
peripheral lymphoid organs (Steinman RM and Cohn ZA, 1973). These dendritic 
cells, as termed by the authors due to their distinct morphology, represent a 
heterogeneous population of antigen-presenting cells and are important in 
immune responses (Banchereau J and Steinman RM, 1998; Wei C, 2005). After 
transplantation, donor dendritic cells migrate immediately from the allograft to 
the regional lymph nodes, where they initiate a robust immune response to the 
allograft leading to acute rejection (direct pathway of allorecognition). A few 
days after transplantation host dendritic cells will process allogeneic MHC 
molecules into peptides and present them in a self-restricted manner to host T 
cells. Besides their extremely powerful ability to initiate immunity, particularly 
dendritic cells are also able to induce antigen-specific unresponsiveness that 
includes deletion and induction of regulatory cells (Banchereau J et al., 2000). 
Therefore, their central role in immunity and tolerance seems to make them the 
ideal cellular candidate for the antigen-specific modulation of the alloimmune 
response after transplantation.  
 
A closer look into the biology of dendritic cells reveals that these properties are 
dependent on their state of maturation (Banchereau J et al., 2000; Kuwana M, 
2002; Zhu M et al., 2003; Nikolic T et al., 2003). Mature dendritic cells are 
extremely powerful activators of naïve T cells since they provide all the signals 
required for their fully activation. The most important costimulatory molecules 
expressed on the cell surface of the dendritic cells are the B7.1 (CD80), B7.2 
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(CD86) and CD40. In contrast, the so-called immature or semi-mature dendritic 
cells induce anergic, non-responsive or regulatory T cells instead of alloreactive 
T cells. The general characteristic of the immature dendritic cells is an inter-
mediate expression of MHC class II coupled with a low or no expression of 
costimulatory molecules (Peche H et al., 2005; Nikolic T et al., 2003). Most of 
the authors described a suppressive or tolerogenic effect of these cells in vitro 
(Lutz MB et al., 2000 [1]; Beriou G et al., 2005). Some of them, for instance 
Grauer (Grauer O et al. 2002), found that immature rat BM-DCs were poor 
stimulators of mixed leukocyte cultures. Powell et al. discriminated two subtypes 
of immature rat BM-DCs, FcR-positive and FcR-negative cells (Powell TJ et al., 
2003). The first ones were poor stimulators and the second ones were excellent 
stimulators of T cell activation. In addition, different studies have also shown the 
ability of immature DCs to induce the prolongation of allograft survival (DePaz 
HA et al., 2003; Garovillo M et al., 2001). 
 
The granulocyte-macrophage colony stimulating factor or GM-CSF is the 
cytokine that appears constantly in most of the protocols used to generate 
dendritic cells. Initially, this cytokine was characterized for its ability to induce 
the in vitro formation of colonies of granulocyte-macrophage progenitors. It is 
produced by activated T cells, B cells, mast cells, macrophages, endothelial 
cells and fibroblasts in response to immune and inflammatory stimuli (Gala RR 
and Shevach EM, 1994; Channon JY et al., 2002). Later, it was demonstrated 
that GM-CSF is able to induce also the formation of dendritic cells. The ability of 
this cytokine to induce the formation of cell clusters seems to be vital for the in 
vitro development of dendritic cells from hematopoetic-lineage precursors. The 
enhancement of DC numbers generated in vitro by the addition of GM-CSF was 
described for the first time by the group of Steinman in 1987 (Witmer-Pack MD 
et al., 1987). Since then, different groups have developed different protocols 
based on the use of GM-CSF alone (DePaz HA et al., 2003) or in combination 
with other cytokines like IL-4 (Menges M et al., 2005) or IL-10 (Commeren DL et 
al., 2003) in order to induce DCs at different maturation stages.  
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2 Aims of the study 
 
The present study analyses the importance of rat dendritic cells with immune 
inhibitory properties (Klinkert WE et al., 1982; Miranda de Carvalho et al., 
2005). The rat is one of the most important animal models for experimental 
organ transplantation in a clinic-relevant procedure (Timmermann W et al., 
1998). Therefore, the main purpose of this study was to characterize immature 
rat dendritic cells and to analyse their regulatory effect in vitro and in vivo.  
 
In general, large numbers of dendritic cells can be propagated for therapeutic 
purposes (Lutz MB et al., 1999) due to the improvements in the isolation of 
dendritic cells and culture techniques. The generation of rat dendritic cells 
derived from bone marrow progenitor has been well documented (Grauer O et 
al., 2002). In the present study, the effect of two protocols, GM-CSF plus IL-4 
and GM-CSF plus IL-10, on the generation of immature dendritic cells was 
analysed. To confirm their expected immature character, their phenotype 
(expression of MHC molecules and costimulatory molecules), their endocytosis 
capacity, and their inhibitory effect on the activation of naïve and antigen-
specific T cells have been investigated.  
 
The results of current clinical trials regarding the use of autologous dendritic 
cells for the induction of anti-tumor immune responses support the idea of using 
dendritic cells as a vehicle to deliver target antigens. In this work the possibility 
of preventing or delaying allograft rejection with autologous tolerogeneic 
dendritic cells pulsed with a relevant allopeptide was analysed. For a certain rat 
model of allograft rejection (Fig. 10.1 in the appendix), the immunodominant 
allopeptide P1 that accelerated graft rejection was identified as an important 
antigen (Sitaru AG et al., 2004). Such a model offers an attractive and practical 
approach to analyse the potential of host immature dendritic cells pulsed with 
P1 to suppress the allograft-induced immune response in an antigen-specific 
manner without the need of chronic immunosuppression. 
 
 10 
Questions 
 
(1) What are the main phenotypic characteristics of immature bone marrow-
derived dendritic cells? 
(2) What is the effect of immature bone marrow-derived dendritic cells on naïve 
and antigen-specific T cells? 
(3) Do P1-pulsed immature bone marrow-derived dendritic cells influence the 
allograft survival in an antigen-specific manner? 
 11 
3 Materials and Methods 
 
3.1 Animals 
Inbred Lewis, Wistar Furth and Brown Norway rats, weighing between 200 and 
350 g, were provided by Harlan Winkelmann GmbH (Borchen, Germany). 
Animal experiments were conducted in accordance with national and 
institutional animal care policies. Dendritic cells and antigen (P1)-specific T cells 
were habitually isolated from Lewis rats (3.5, 3.6, and 3.7). In addition, inbred 
male rats from Lewis, Wistar Furth and Brown Norway strains were used in the 
transplantation experiments (3.14). 
 
3.2 The allogeneic peptide P1 
The Wistar Furth (WF) MHC class I (RT1.Au) peptide P1 was previously 
characterized (Sitaru AG et al., 2002). The immunization of Lewis rats with P1 
previous to transplantation reduced the survival of Wistar Furth grafts from 7.3 ± 
0.5 to 5.2 ± 0.4 days (Figure 10.1). P1 was synthesized by Jeriny AG (Berlin, 
Germany) based on published sequences (Joly E et al., 1995; Chowdhury NC 
et al., 1998) with a purity of 95%. The lyophilized peptide was dissolved in 
sterile PBS at 1.0 mg/ml and stored at -20°C. P1 is a 19-mer peptide located in 
the β-plate of the α1 domain of the RT1.Au (Figure 10.1). The different amino 
acids between P1 and the corresponding region of the MHC class I molecule of 
the Lewis rat are located in positions 5, 9 and 10 (Table 3.1). Subsets of 
alloreactive Lewis T cells recognize these amino acids (Sitaru AG et al., 2004).  
 
Table 3.1: Comparison of the amino acid sequence between peptide P1 and the first 19 amino 
acids of MHC class I of Wistar Furth (RT1.Au) and Lewis (RT1.Al) in one-letter code. The 
identical amino acids are represented by bars, the different amino acids by letters. The numbers 
indicate the position of the amino acid residues in the molecule. 
 
Amino acid sequence 
  
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 
P1 G S H S L R Y F L T A V S R P G L G E 
RT1.Au (1-19) − − − − L − − − L T − − − − − − − − − 
RT1.Al (1-19) − − − − M − − − D I − − − − − − − − − 
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3.3 Immunization 
Lewis rats were immunized in the hind footpad with 12.5 µl (= 12.5 µg) of pep-
tide P1 (working stock solution: 1 mg/ml) combined with an equal volume of the 
adjuvant TiterMax (Alexis GmbH, Grünberg, Germany). The animals were 
anaesthetized with Isofluran (Abbot GmbH, Wiesbaden, Germany) shortly 
before immunization. 
 
3.4 Culture medium and buffers 
Culture medium 
Roswell Park Memorial Institute (RPMI) 1640 cell culture medium (Gibco/ 
Invitrogen, Karlsruhe, Germany) was used as the standard culture medium 
supplemented with 20 mmol/L HEPES, 1 mmol/L sodium pyruvate, 2 mmol/L L-
glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 5x10-5 mol/L 2-
mercaptoethanol, 1% non-essential amino acids and 10% fetal calf serum or 
FCS (all reagents provided by Gibco/Invitrogen, Karlsruhe, Germany). All 
concentrations are indicated as final concentrations. 
 
Phosphate-buffered saline (PBS) 
The phosphate-buffered saline (pH 7.2) contains a mixture of 140 mmol/L 
sodium chloride, 2.7 mmo/L potassium chloride, 7.2 mmol/L sodium dihydrogen 
phosphate and 1.47 mmol/L potassium hydrogen phosphate. The solution was 
sterilized and kept at 4°C. 
 
Lyse buffer (10-fold concentrated) 
The erythrocyte lyse buffer (diluted 1:10 with sterile aqua injectabila) contains 
1.68 mol/L ammonium chloride, 99.88 mmol/L potassium hydrogen carbonate 
and 12.6 mmol/L EDTA. 
 
Tris-NaCl buffer 
The Tris-NaCl buffer was used for immunohistochemistry procedures (3.13). 
The buffer consists of 0.6 g/L Tris-HCl and 8.1 g/l NaCL. Bovine serum 
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albumine (BSA) was added to the solution in a final concentration of 2 g/L. The 
pH was adjusted to 7.4. 
 
3.5 Generation of bone marrow-derived immature dendritic cells 
Bone marrow was extracted from femur and tibia bones of young (8-10 weeks) 
Lewis rats. The bones, cleaned of muscular tissues with a scalpel, were 
disinfected for 3 minutes in 70% alcohol and washed 2 times in sterile PBS. 
Both ends of the bones were cut off with scissors. The bone marrow was 
flushed with culture medium through a 70 µm nylon cell strainer (Becton Dickin-
son Biosciences, Heidelberg, Germany) into a Falcon tube using a syringe with 
a 20-gauge needle. The bone marrow cells, washed three times without lysing 
the red blood cells, were cultured in Petri dishes (Falcon, Becton Dickinson Bio-
sciences) with a diameter of 100 mm or in the cavities of 6 well-plates (Greiner 
bio-one, Frickenhausen, Germany) at a cell density of 5x105 cells/ml. The fol-
lowing cytokines were added to the cultures (final concentration): 5 ng/ml 
recombinant rat granulocyte-macrophage colony stimulating factor (rGM-CSF, 
R&D Systems, Heidelberg, Germany or Biosource, Camarillo, California, USA); 
5 ng/ml recombinant rat interleukin-4 (rIL-4, Strathmann Biotech AG, Hamburg, 
Germany) or 5 ng/ml interleukin-10 (rIL-10, Strathmann Biotech AG). On day 4, 
half of the medium was substituted with fresh medium without cytokines. On 
day 6 the non-adherent and light-adherent cells were collected and centrifuged 
over 14.5% metrizamide (Linaris Biologische Producte GmbH, Wertheim, 
Germany) at 4°C and 1,823 xg for 13 minutes. The immature DC were gently 
collected from the interface and counted. Maturation was induced with bacterial 
lipopolysaccharide or LPS (Sigma, Deisenhofen, Germany) in a final concen-
tration of 20 ng/ml for 24 h.  
 
Table 3.2: The cytokines used for the induction of immature BM-DCs and their corresponding 
name. 
Cytokines  Corresponding name 
GM-CSF+IL-4 IL-4 DC 
GM-CSF+IL-10 IL-10 DC 
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3.6 Isolation of splenic dendritic cells  
Splenic dendritic cells (= S-DCs) from naïve Lewis rats were used as mature 
antigen-presenting cells. The spleens were prepared mechanically through a 70 
µm nylon cell strainer (Becton Dickinson Biosciences) and the erythrocytes 
were lysed with lyse buffer. The leukocytes were incubated overnight in culture 
medium at 37°C in a 5% humidified CO2 atmosphere. The non-adherent cells 
were collected and centrifuged over a 14.5% metrizamide gradient in order to 
enrich the dendritic cells on the interface. 
 
3.7 Isolation of antigen-specific lymph node cells 
Popliteal lymph node cells of P1-immunized Lewis rats were isolated 7 days 
after immunization and prepared mechanically with a 10 ml syringe piston 
through a 70 µm nylon cell-strainer (Becton Dickinson Biosciences). After 
washing twice, the viable cells (they did not incorporate trypan blue) were 
counted in the Neubauer chamber.  
 
3.8 In vitro assay systems 
3.8.1 Proliferation assay for naïve T cells 
Naïve T cells (105 cells/well) from lymph nodes of Wistar Furth or Brown 
Norway rats were incubated with irradiated (20 Gy) Lewis mature splenic DCs 
(104 cells/well) in a final volume of 150 µl. The 96-well round-bottom plates were 
incubated for 3 days at 37°C in a 5% humidified CO2 atmosphere and pulsed 
with 0.5 µCi/well [3H]-thymidine (Biomedicals Germany GmbH, Eschwege, 
Germany) for the last 6 hours of culture. Control wells consisted of naïve T cells 
cultured alone. The incorporation of [3H]-thymidine was measured with the scin-
tillation method (3.8.2). The ability of IL-4 DCs and IL-10 DCs to activate naïve 
T cells was tested in this assay (mixed leukocyte culture or MLC). 
 
3.8.2 T cell proliferation assay for activated T cells 
P1-specific Lewis lymph node cells (105 cells/well) were incubated with splenic 
DCs (104 cells/well) loaded with P1 (1.25 µg/well or 8.33 µg/ml) in 96-well 
round-bottom plates. The final volume was 150 µl in each well. The DCs were 
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irradiated with 20 Gray (Institut für Strahlenkunde, Würzburg). The plates were 
incubated for 3 days at 37°C in a 5% humidified CO2 atmosphere and pulsed 
with 0.5 µCi/well [3H]-thymidine for the last 6 hours of culture. The incorporation 
of [3H]-thymidine by the proliferating T lymphocytes was measured with the 
scintillation procedure. For this, the cells were harvested with the MicroBeta 
Filtermat-96 cell harvester (Wallac, Turku, Finland) and their DNA was collected 
on special filter paper (1450-421 Filtermat A, Wallac, Perkin-Elmer Life and 
Analytical Sciences, Rodgau, Germany). The filter paper was dried for 1 hour 
and then sealed in special plastic bags (Wallac, PerkinElmer) with liquid scin-
tillation. The [3H]-thymidine incorporation was measured with a Wallac-
MicroBeta TriLux β-radiation counter (Institut für Virologie und Immunbiologie, 
Würzburg). Control wells consisted of P1-specific T cells cultured alone. The 
experiments were set up in 6-12 replicates and the results (mean ± standard 
deviation) were expressed in counts per minute (cpm). The ability of IL-4 DCs 
and IL-10 DCs to restimulate antigen-specific T cells was tested in this assay. 
 
3.8.3 Restimulation of antigen-specific T cells after incubation with 
immature BM-DCs (restimulation assay) 
This assay proved the ability of P1-T cells, which were pre-incubated with IL-4 
DCs or IL-10 DCs, to proliferate in the presence of P1-loaded mature splenic 
DCs. The P1-T cells were incubated with P1-loaded IL-4 DCs and IL-10 DCs, 
respectively, in a cell ratio of 1 DC to 2 T cells for 3 days. For depletion of DCs 
the cells were incubated with Ox-42 (Table 3.3) for 20 minutes on ice on the 
rocking platform. The cells, washed 2 times with PBS, were incubated with 
paramagnetic polymer beads (CELLection Pan Mouse IgG Kit; Dynal, Hamburg, 
Germany) for 20 minutes on ice and, afterwards, the bead-coated DCs were 
depleted with a magnet. The T cells remaining in the supernatant were collected 
(purity > 90%) and transferred to the T cell proliferation assay. After incubation 
for 3 days, the plates were pulsed with 0.5 µCi/well [3H]-thymidine for the last 6 
hours of the culture. The incorporation of radioactivity was measured using a 
beta-radiation counter as previously described (3.8.2). 
 16 
3.8.4 T cell mediated inhibition after incubation with immature BM-DCs 
(inhibition assay) 
P1-specific T cells were incubated with P1-pulsed IL-4 DCs or IL-10 DCs in a 
cell ratio of 1 DC to 2 T cells for 3 days in culture dishes with 10 mm diameter. 
After depletion of DCs the purified T cells (termed as DC-Ts) were transferred to 
the T cell proliferation assay (P1-specific T cells and P1-pulsed splenic DCs). 
Different cell numbers (from 101 to 105) of these DC-Ts were tested for their 
possible regulatory or inhibitory properties on freshly isolated P1-specific T cells 
in the proliferation assay. The cells were cultured for 72 h and pulsed with [3H]-
thymidine for the last 6 h of culture. The incorporation was measured as 
described before (3.8.2). 
 
3.9 Flow cytometric analysis 
3.9.1 Phenotyping 
For the flow cytometric analysis, 5x105 cells (in 50 µl PBS) were incubated for 
20 minutes at 4°C with the optimal concentrations of specific antibodies. The 
antibodies (Table 3.3) were conjugated with fluorescein isothiocyanate (FITC) or 
phycoerythrine (PE). The non-conjugated antibody Ox-62 and the CTLA-4Ig 
fusion protein were detected with the FITC-conjugated secondary antibody 
donkey anti-mouse (Dianova, Germany). The nonviable cells were identified 
with 7-amino actinomycin D (7-AAD) (Becton Dickinson Biosciences). The non-
specific binding was controlled with isotype control antibodies. The samples 
were measured using an argon-laser flow-cytometer FACSscan (Becton 
Dickinson Biosciences). The analysis was performed with WinMDI, Version 2.8. 
 
3.9.2 Determination of antigen uptake by dendritic cells 
The ability of IL-4 and IL-10 DCs to take up antigens was tested using FITC-
conjugated Dextran (Sigma-Aldrich, Germany) at 1 µg/ml (diluted with PBS) and 
fixed cells as negative control. FITC-conjugated dextran was added to the wells 
and incubated at 37°C for 6 and 24 hours.  
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Table 3.3: Antibodies and fusion protein for phenotyping of rat dendritic cells by flow cytometry 
and immunohistochemistry (3.13). 
*
)
 nonlytic mouse CTLA-4Ig fusion protein [mCD152 (CTLA-4)Ig] consisting of the extracellular 
domain of mouse CD152 fused to the Fc portion of mutant mouse IgG2a. 
 
3.10 Reverse transcriptase-polymerase chain reaction (RT-PCR) 
Total RNA was isolated from 106 cells with 1 ml of the ready-to-use reagent 
Trizol Reagent (Invitrogen GmbH, Karlsruhe, Germany) according to the 
manufacturer's recommendations. The addition of chloroform (Carl Roth GmbH, 
Karlsruhe, Germany) followed by centrifugation (15 minutes, 16,000 xg, at 4°C) 
separated the solution into an aqueous phase containing exclusively the RNA, 
and an organic phase. The RNA was recovered after precipitation with Isopro-
panol (Merck Eurolab, Nürnberg, Germany) overnight at -20°C. After centrifu-
gation the pellet was washed with Ethanol (Merck Eurolab). The air-dried RNA 
was dissolved in 40 µl RNA storage solution (Ambion (Europe), Huntingdon, 
United Kingdom) and stored at -80°C. The cDNA synthesis was performed by 
reverse transcription of 5 µl RNA with reverse-transcriptase (2.5 U/µl) and Oligo 
d(T)16 primer (2.5 µmol/L), using the GeneAmp RNA-PCR-Kit (Applied Bio-
systems GmbH, Weiterstadt, Germany). Five µl cDNA was amplified using Gold
 
AmpliTaq DNA-Polymerase (0.05 U/µl) and the specific primers (5 µmol/L each) 
(Table 3.4) mixed in nuclease free water (Promega GmbH, Mannheim, 
Germany) to an end volume of 50 µl per sample. Ten µl PCR product mixed 
with 1.5 µl Blue/Orange 6x loading dye (Promega GmbH) was transferred to an 
ethidium bromide loaded 2% agarose gel (Amresco, Solo, Ohio, USA). The gel 
 
Antibody Specificity Distributor 
 
Ox-1 CD45 
 
Ox-6 MHC II (RT1B) 
 
Ox-22 CD45RC 
 
Ox-42 CD11b/c 
 
Ox-62 α-E2 Integrin 
 
ED-1 CD68 
 
Linaris Biologische 
Produkte, Wertheim-
Bettingen 
 
CTLA-4Ig *) CD80/CD86  Alexis Biochemicals  Cat.-No: CHI-MF120A4-M001 
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was run at 80 volt for 30 minutes and the separated PCR products were photo-
graphed in the gel with UV light illumination (ImageMaster workstation from 
Amersham Pharmacia Biotech, Piscataway, USA). The house-keeping gene 
Glycerinaldehyd-3-Phosphat-Dehydrogenase (GAPDH) was used as positive 
control. 
 
3.11 Real time PCR 
The SYBR Green kit from Applied Biosystems was used to quantify the 
expression of MHC class II mRNA. From the cDNA (3.10) probes were ampli-
fied in the Opticon 2 Cycler (M.J. Research, Bio-rad, USA). SYBR Green was 
used as a fluorescence reporter for the double stranded DNA and the signal 
increased in direct proportion to the amount of the PCR product. A melting 
curve was performed to analyse product homogeneity. For absolute 
quantification calibration curves of GAPDH and MHC II was performed. For this, 
both the Taq-amplified PCR products of GAPDH and MHC II (Table 3.4) were 
ligated into the PCR vector (TA cloning kit from Invitrogen GmbH, Karlsruhe, 
Germany) and the constructs were transformed into TOP10F´ chemically com-
petent E. coli. Colonies from the plates were picked after 24 h and were grown 
overnight in liquid cultures with ampicillin as selection antibiotic. The extracted 
plasmid DNA (QIAprep Spin Minipreps from QIAGEN, Hilden, Germany) was 
checked for the inserts and the concentration was determined by measuring the 
absorbance at 260 nm. The calibration curves were performed in the range from 
102 to 108 start molecules (start copy number against threshold cycle or Ct). The 
reactions were performed in special tubes (thin-wall 8-tube strips from Biozym, 
Hess. Oldendorf, Germany) and the process was repeated 3 times for each 
sample. 
 
Table 3.4 (next page): The sequences of the primers used in the work. The forward and 
backward sequence is presented for each of the primers. All the primers were synthesized by 
MWG Biotech AG (Ebersberg, Germany) according to published sequences: GAPDH (Krusse 
JJ et al., Cytokine 1999); IL-2 (McKnight AJ et al., J Immunol Methods 1989); IL-4 (Siegling A et 
al., J Immunol Methods 1994); IL-10 (Siegling A et al., J Immunol Methods 1994); IL-12 
(Stumbles P A et al., J Exp Med 1998); IL-13 (Gillespie KM et al., Eur J Immunol 1996); IFN-γ 
(Dijkema R et al. Meth Enzymol 1986); MHC class II (Syha-Jedeljauser J et al., Biochem 
Biophys Acta 1991); CD40 (Yutake Matsui et al., J Mol Cell Cardiol 2002); CD80 (Holowachuk 
E.W. et al., Biochem and Biophys Research Comm 2001); CD86 (self made with GeneFisher). 
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Primer bp Temp Sequence 5´→ 3´ 
 for GGT CGG TGT GAA CGG ATT TG GAPDH 319 62 
 
rev GTG AGC CCC AGC CTT CTC CAT 
 for GCG CAC CCA CTT CAA GCC CT IL-2  351 62 
 
rev CCA CCA CAG TTG CTG GCT CA 
 for AGT CAA CAC CCT AAC ATC AGG G IL-4 547 60 
 
rev GGC CTC AAA CAG CTC CAT ACA G 
 for CTC GCT TCA CAG TGG ATG AA IL-10  371 55 
 
rev TAA ATA CGG TGG TGC GTG AA 
 for TGG AGT CAT AGG CTC TGG A IL-12 484 58 
 
rev GAT GAA GAA GCT GGT GCT G 
 for CAG GGA GCT TAT CGA GGA GC IL-13  280 55 
 
rev AAG TTG CTT GGA GTA ATT GAG C 
 for CCC TCT CTG GCT GTT ACT GC IFN-γ 419 62 
 
rev CTC CTT TTC CGT TTC CTT AG 
 for CAG GAT CTG GAA GGT CCA MHC II  517 55 
 
rev AGC TGT GGT TGT GCT GA 
 for CGC TAT GGG GCT GCT TGT TGA CAG CD40 401 58 
 
rev GAC GGT ATC AGT GGT CTC AGT GGC 
 for TGG TGA AAC ACC TGA CCA CD80  517 50 
 
rev GTT TCT CTG CTT GCC TCA 
 for TGG GAA ACA GAG CTC TCA CD86  518 53 
 
rev AGG TTG ATC GAC TCG TCA 
bp = base pair; Temp = annealing temperature of the primer in °C. 
 
 
3.12 ELISA  
Purified IL-4 and IL-10 DCs from day 6 of culture were replated in 96-well plates 
(105 cells/well in a final volume of 150 µl) without exogenous cytokines and 
stimulated for 24 hours with 20 ng/ml LPS. The presence of IL-10 and IL-12 in 
the supernatant was checked using the BioSource kits (Ratingen, Germany): IL-
12 (p40 and p70): KRC0121; IL-10: KRC0101.  
 
3.13 Immunohistochemistry 
Purified day 6 IL-4 DCs and IL-10 DCs (5x105 cells per slide (cytospin) or 
cultured on glass slides) were air-dried. After fixation in acetone for 10 minutes 
the preparations were incubated overnight with the following anti-rat monoclonal 
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antibodies and fusion protein (Table 3.3) diluted in background reducing buffer 
(DAKO Cytomation, Hamburg, Germany): OX-62 (rat-dendritic cell marker) 
1:50; OX-6 (MHC class II) 1:200; ED1 (macrophage marker) 1:200; CTLA-4Ig 
fusion protein (CD80/CD86) 1:50. The next day the slides were washed and 
incubated with a mix of 1:50 peroxidase-conjugated rabbit anti-mouse antibody 
(DAKO) and rat serum in a final volume of 200 µl per slide for 1 hour and then 
washed again. The preparations were incubated with hydrogen peroxidase and 
diaminobenzidine (Liquid DAB, BioGenex, San Ramon, USA), counterstained 
with hematoxilin and eosin (H&E) and embedded with Entelan (Merk, Darm-
stadt, Germany).  
 
3.14 In vivo transfer of bone marrow-derived immature dendritic cells 
and heterotopic heart transplantation 
The possible influence of IL-4 DCs or IL-10 DC on allograft survival was tested. 
Therefore, 10x106 cells (P1-pulsed and unpulsed cells) were transferred sub-
cutaneously into Lewis rats one day before transplantation. They were 
incubated with 20 µg P1 for 30 minutes in 500 µl PBS and then washed 2 times 
with PBS. On "day 0" the animals received hearts from Wistar Furth donors in a 
heterotopic position according to the method of Ono and Lindsey (Ono K and 
Lindsey ES, 1969) using standard microsurgical techniques. The donor ascen-
ding aorta and the pulmonary trunk were anastomosed end-to-side to the re-
cipient infrarenal abdominal aorta and inferior vena cava. The allograft survival 
was monitored by daily abdominal palpation of cardiac contractions. A complete 
loss of palpable ventricular contractions was considered to be rejected. No 
immunosuppression was administered. 
 
Figure 3.1: The dendri-
tic cell transfer proto-
col. Ten million IL-4 or 
IL-10 DCs were pulsed 
with 20 µg peptide P1 
and injected into a 
Lewis recipient one day 
before organ trans-
plantation. 
WF
heart
d -1 d 0
10x106 DC i.v.
pulsed with P1
Transplantation
Allograft
survival
Lewis
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4 Results 
 
4.1 Generation of bone marrow-derived immature dendritic cells 
Femurs and tibias were extracted from 8 to 10 week old male Lewis rats and 
approximately 12 x 107 to 15 x 107 bone marrow cells (Figure 4.1) were flushed 
out from the four bones (n = 50 animals). The bone marrow cells were cultured 
in a cell density of at least 5 x 105 cells per ml (Table 4.1). With this starting cell 
number, approximately 2.5 x 106 to 4.0 x 106 bone marrow-derived dendritic 
cells were isolated from each petri-dish at the end of the 6-day culture period. 
 
Figure 4.1: The morphology of bone marrow cells. Freshly isolated bone marrow cells in 
culture (left, x200, phase contrast microscopy) and after H&E staining (right, x600 plus digital 
magnification with Corel Photo-Paint 11). For the H&E staining most of the red blood cells which 
appeared as dim cells in the culture (left) were lysed.  
 
 
 
After 6 days in culture with GM-CSF plus IL-4 or GM-CSF plus IL-10 the 
recovered non-adherent cells were purified over a 14.5% metrizamide gradient 
and the dendritic cells were enriched at the interface (Figure 4.2). The flow 
cytometric analysis of these cells exhibited a large forward scatter or FSC and a 
low side scatter or SSC (Figure 4.7 and Table 10.6 in the appendix). In addition, 
these cells, stained by the monoclonal antibody Ox-1, were CD45-positive (not 
shown). 
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Table 4.1: The density of bone marrow precursor cells strongly influence the formation of 
cell clusters during the period of culture. The best results were obtained with a cell density 
between 5.0 x 105 and 7.5 x 105 cells/ml. A lower cell density was not able to induce the 
formation of cell clusters and a density around 106 cells/ml did not increase the number of cell 
clusters and, in consequence, the yield of immature DCs. Data from 6 different experiments are 
shown. 
Bone marrow cells 1)  Cluster formation Number of harvest cells 2) 
< 5 x 105 No < 0.1 x 106 
5 x 105 - 7.5 x 105 Yes 2.5 x 106 - 5 x 106 
> 106 Yes 2.5 x 106 - 5 x 106 
1)
 Number of seeded cells per ml. 
2)
 Per culture dish (100 mm ∅ from Falcon, Becton Dickinson Biosciences) with 15 ml culture 
medium.  
 
 
The cells purified from the cultures with GM-CSF and IL-4 (= IL-4 DCs) were 
separated into two layers: a low density cell population at the interface and a 
high density cell population at the bottom of the tube (Figure 4.2 and Table 4.2). 
In contrast, all DCs cultured with GM-CSF and IL-10 (= IL-10 DCs) remained at 
the interface and no pellet was observed. This might indicate that a more 
homogenous cell population was obtained with GM-CSF and IL-10 in contrast to 
GM-CSF and IL-4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Centrifugation over metrizamide 
 Interface Pellet 
IL-4 DCs *) Yes Yes 
IL-10 DCs *) Yes No 
 
 
Figure 4.2: The metrizamide puri-
fication of day 6 immature BM-
DCs. The low-density cells accu-
mulated at the interface between 
medium and metrizamide (arrow). 
Table 4.2: Purification of immature BM-DCs over 
metrizamide.(*) IL-4 DCs: culture medium with GM-
CSF plus IL-4; IL-10 DCs: culture medium with GM-
CSF plus IL-10 (Table 3.2). Some of the IL-4 DCs 
passed the metrizamide and were also found at the 
bottom of the tube, whereas all IL-10 DCs remained at 
the interface. 
 23 
Both the density of the seeded bone marrow cells and the cytokines added to 
the cultures seem to influence the yield of immature DCs. Therefore, different 
culture conditions were tested in order to maximize the yield of bone marrow-
derived dendritic cells (Table 4.3). The granulocyte-macrophage colony stimu-
lating factor (GM-CSF) alone was not able to induce the formation of high 
numbers of BM-DCs. The addition of IL-4 or IL-10 to the cultures was a key 
factor for the development of immature BM-DCs. It seems that IL-10 induces 
the formation of fewer cell colonies in comparison with IL-4. In addition, IL-10 
DCs were not as adherent as IL-4 DCs. Higher numbers of immature BM-DCs 
were usually recovered from the IL-4 cultures (up to 5 x 106 cells per culture 
dish) in comparison to IL-10 DCs (up to 3.5 x 106 cells per culture dish). Both IL-
4 DCs and IL-10 DCs showed a comparable phenotype on day 6 of culture 
(Figure 4.3). 
 
Table 4.3: The effect of different concentrations of cytokines on the development of IL-4 
DCs and IL-10 DCs. The best results concerning the amount of harvested cells were obtained 
in the presence of 5 ng/ml GM-CSF plus 5 ng/ml IL-4 and GM-CSF plus IL-10 (each 5 ng/ml). 
Higher concentrations (around 10 ng/ml) did not increase the number of BM-DCs and lower 
concentrations (under 5 ng/ml) were unable to induce the formation of BM-DCs at all. Data from 
six different experiments are shown. 
Cytokine concentration 1) Cell cluster formation Number of harvest cells 2) 
GM-CSF 
5 ng/ml Yes < 0.1 x 10
6
 
GM-CSF+IL-4 
< 5 ng/ml No < 0.5 x 10
6
 
GM-CSF+IL-4 
5 ng/ml Yes 4.0 x 10
6
 - 5.0 x 106 
GM-CSF+IL-4 
> 10 ng/ml Yes 4.0 x 10
6
 - 5.0 x 106 
GM-CSF+IL-10 
< 5 ng/ml No < 0.1 x 10
6
 
GM-CSF+IL-10 
5 ng/ml Yes 2.5 x 10
6
 - 3.5 x 106 
GM-CSF+IL-10 
> 10 ng/ml Yes 2.5 x 10
6 
- 3.5 x 106 
1)
 Final concentration. 
2)
 Per culture dish (100 mm ∅ from Falcon, BD Biosciences) with 15 ml culture me
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Figure 4.3: The morphology of IL-4 DCs and IL-10 DCs. Typical morphology of IL-4 DCs (left) 
and IL-10 DCs (right) on day 6 of culture (H&E staining). Small- to medium-sized round cells 
represent the main morphology in the cell cluster (contaminating fibroblasts are not shown). 
Magnification: x600 plus a 2-fold digital magnification (IL-10 DCs) with Corel Photo-Paint 11. 
 
 
Under the influence of the cytokine combinations GM-CSF and IL-4 or GM-CSF 
and IL-10 some of the bone marrow cells started to proliferate within 24 hours. 
These enlarged cells were characteristic for the first two days of culture. Some 
of them were still floating while others became adherent. No cell clusters were 
observed at this early time point (Figure 4.4). Around day 3-4, some of the cells 
started to form adherent cell clusters and on day 6 of culture, the cells 
developed large clusters (Figure 4.4). They became less adherent after day 8 
and most of the cells were easily dislodged by pipetting. A longer period of 
culture (day 10) was not able to improve the yield of immature BM-DCs. Both 
IL-4 DCs and IL-10 DCs showed similar characteristics during their culture. In 
addition, these cells did not mature during the 10 days of culture.  
 
Most of the cells isolated from the clusters had a very similar phenotype: they 
were small, round and mononucleated (Figure 4.3). The cells growing outside 
the clusters were large mononucleated cells with a round or irregular cytoplasm. 
Most of these very strong adherent cells were fibroblasts as demonstrated by 
the positive staining with the monoclonal antibody 6-9H6 with specificity to rat 
prolyl 4-hydroxylase (not shown). In general, these fibroblast-like cells could not 
be isolated just by pipetting.  
 
 25 
Figure 4.4: Representative changes in the culture morphology of immature IL-4 DCs and 
IL-10 DCs. Between day 3 and 4 the first cell clusters were seen and most of the cells were 
already developing in clusters around day 6. Outside the clusters, the fibroblasts were forming 
 
IL-4 DCs 
day 1 
day 6 
day 10 
day 1 
day 6 
day 10 
IL-10 DCs 
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an adherent cell layer (magnification: x200 using an Olympus IMT-2 microscope. Images were 
captured using an Olympus digital camera C-5050 and processed with Corel Photo-Paint 11). 
Especially during the first days of culture, contaminating red blood cells were visible as dim cells 
(Figure 4.1).  
 
 
 
The maturation of the bone marrow DCs was induced by incubation with 
bacterial LPS in a final concentration of 20 ng/ml for 24 hours. In contrast to 
immature BM-DCs, the mature BM-DCs were able to restimulate antigen (P1)-
specific T cells in the T cell proliferation assay (Figure 4.5). The strength of the T 
cell proliferation with 16,000 ± 2,800 cpm was similar to the proliferation 
induced by mature S-DCs (18,000 ± 2,000 cpm). The RT-PCR analysis 
confirmed their mature phenotype by showing strong signals for the expression 
of MHC class II molecules and costimulatory molecules. However, as 
demonstrated in chapters 4.2 and 4.3, the presence of specific mRNA for 
costimulatory molecules was not an exclusive feature of the mature BM-DCs.  
 
 
Figure 4.5: The comparison between mature splenic DCs and immature BM-DCs. Day 8 
BM-DCs treated for 24 hours with LPS (Figure 4.7) became excellent stimulators of T cell 
proliferation in the T cell proliferation assay (left diagram). Mature splenic DCs (S-DCs) and 
immature BM-DCs were used as controls. The T cell proliferation is represented as [³H]-
thymidine incorporation in counts per minutes (cpm). The diagram shows the results of one 
experiment (with mean and standard deviation) representative for a series of three. Both, IL-4 
DCs and IL-10 DCs matured and acted similarly in the presence of LPS; therefore, only the 
results for IL-4 DCs are shown. The T cell proliferation assay is described in the chapter 
“Materials and Methods” (3.8.2). Specific mRNA for MHC class II molecules and costimulatory 
molecules was found in the mature BM-DCs. A representative RT-PCR analysis of three is 
shown on the right. Supplementary information on the PCR products can be found in the 
chapter “Material and Methods” (Table 3.4).  
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As shown in Figure 4.5, the immature dendritic cells are weak stimulators of 
antigen-specific T cells. To analyse whether this effect is really mediated by the 
immature dendritic cells and not by the fibroblasts and macrophages which are 
also components of the cell cultures (chapter 4.1), the different cell types were 
tested for their possible effect on antigen-specific T cell proliferation. The results 
in Figure 4.6 clearly demonstrate that immature IL-4 DCs and IL-10 DCs were 
not able to restimulate antigen-specific T cells in the proliferation assay in 
comparison to mature S-DCs (51,500 ± 4,600 cpm): 2,900 ± 1,000 cpm for IL-4 
DCs and 2,700 ± 1,100 cpm for IL-10 DCs. In contrast, it seems that macro-
phages and fibroblasts have almost no influence on the antigen-specific T cell 
proliferation (macrophages: 22,000 ± 7,100 cpm and fibroblasts: 14,000 ± 2,900 
cpm). However, the comparison with the results of the autostimulation 
(activated T cells incubated with P1 but without DCs (∅); the grey bar in Figure 
4.6) shows no or only slight differences for fibroblast and macrophages, 
respectively. Antigen-specific T cells are capable of autostimulation since they 
express MHC class II molecules and therefore they are able to present P1 and 
to restimulate each other. With 14,300 ± 4,400 cpm, the strength of the T cell-
mediated autostimulation represented approximately ¼ of the DC-mediated T 
cell activation (51,500 ± 4,600 cpm). In contrast to macrophages and 
fibroblasts, the IL-4 DCs and IL-10 DCs do not restimulate the antigen-specific 
T cells and prevent their autostimulation (Figure 4.6).  
 
Figure 4.6: The comparison of different 
subsets of stimulator cells concerning 
their ability to induce T cell proliferation.
IL-4 DCs and IL-10 DCs were clearly not able 
to induce the restimulation of antigen-specific 
T cells, whereas the mature S-DCs induced a 
strong T cell restimulation. Fibroblasts (F) did 
not influence the T cell restimulation and 
macrophages had a moderate effect in 
comparison to the strength of autostimulation 
(∅; see also text). The value of non-restimu-
lated antigen-specific T cell proliferation was 
2,100 ± 500 cpm (not shown). The results are 
represented as mean ± standard deviation 
(n = 2 per group). 
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Both IL-4 and IL-10 DCs expressed mRNA encoding for the Toll-like receptor 4 
or TLR4 (RT-PCR data not shown). TLR4 is a critical component of the 
heteromeric receptor complex that transduces signals delivered by lipopoly-
saccharide (LPS) of gram-negative bacteria. On the other hand, the LPS 
treatment is a very stressful procedure for the rat BM-DCs. The use of a 
concentration higher than 20 ng/ml LPS (as final concentration) or an incubation 
over 24 hours induced apoptosis in most of the cells (Figure 4.7). 
 
 
Figure 4.7: The effect of LPS on the vitality of immature BM-DCs. In combination with a 24 
hour incubation time 20 ng/ml LPS provided the best results. In contrast, a prolongation of the 
incubation time to 48 hours induced cell death in most of the cells. The picture shows the 
alterations in cell size and cell granularity (FSC vs. SSC), the strength of the cell surface 
expression of MHC class II (Ox-6) and the cell vitality determined by staining with the 
fluorogenic dyes fluorescein diacetate (FDA) and propidium iodide (PI): green cells are vital 
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cells and red cells are dead cells. The numbers on the top of the histograms indicate the mean 
fluorescence intensity of MHC class II molecules on the cell surface. Magnification: x200 using 
an Olympus BX 50 microscope. Images were captured using a digital camera and processed 
with Corel Photo-Paint 11. The data are representative for three independent experiments. 
 
 
 
A further effect induced by the incubation with LPS on IL-4 DCs and IL-10 DCs 
was the induction of IL-10 and IL-12 production. Both cytokines were detected 
in the supernatant with specific ELISA kits from Biosource.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8: The LPS-induced production of IL-10 and IL-12 by IL-4 DCs and IL-10 DCs. For 
this, 105 cells/well of a 96-well plate were stimulated for 24 hours in a final volume of 150 µl. The 
amount of IL-10 (*) and IL-12 were measured with specific ELISA. The results (mean ± standard 
deviation) shown are of one experiment in triplicate wells. The values (pg/ml) are: IL-4 DCs: 
12.4 ± 0.4; IL-10 DCs: 130 ± 2; IL-4 DCs + LPS: 138 ± 1.9; IL-10 DCs + LPS: 216 ± 1.8. 
 
 
The results demonstrate that immature BM-DCs produced IL-12 in response to 
the LPS treatment. The results for IL-4 DCs are shown in the right diagram of 
Figure 4.8: 45 ± 5 pg/ml IL-12 for non-treated IL-4 DCs and 1,576 ± 20 pg/ml IL-
12 after the 24 hours treatment with LPS. IL-12, a heterodimeric cytokine, plays 
an important role in the induction of T-helper 1 (Th1) responses. The RT-PCR 
results in Figure 4.11 revealed that the immature IL-4 DCs and IL-10 DCs 
expressed no mRNA encoding for IL-12. 
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4.2 Characterization of bone marrow-derived immature dendritic cells 
 
4.2.1 The flow cytometric analysis demonstrates single bone marrow-
derived dendritic cells with low surface expression of costimulatory 
molecules 
The phenotypes of immature BM-DCs and splenic DCs, as typical mature DCs, 
were compared. The flow cytometric analysis showed that both immature and 
mature DCs were positive for Ox-62 (an integrin-like molecule used as a marker 
for rat DCs) as well as for Ox-42 (binds CD11b/c molecule on the surface of 
dendritic cells and macrophages). The comparison of the fluorescence intensity 
for Ox-62 indicates that IL-4 DCs and IL-10 DCs have reduced expression 
levels of the integrin-like molecule. 
 
Most of the IL-4 DCs and IL-10 DCs expressed MHC class II molecules on their 
cell surface as shown by staining with the monoclonal antibody Ox-6 (anti-MHC 
class II). However, in comparison to mature S-DCs their surface expression of 
MHC class II was decreased 10-fold (Figure 4.9). In addition, both subtypes had 
a low surface expression of the costimulatory molecules CD80 and CD86 as 
shown when stained with the CTLA-4Ig fusion protein (anti-CD80/86). The 
expression of costimulatory molecules was clearly lower than on mature splenic 
DCs. No difference in the surface expression of MHC class II or CD80 and 
CD86 was found between IL-4 DCs and IL-10 DCs. In summary, the phenotype 
of IL-4 DCs and IL-10 DCs was very similar. 
 
 
 
 
Figure 4.9 (next page): Flow cytometric phenotyping of immature IL-4 DCs and IL-10 DCs 
in comparison to mature S-DCs. The immature BM-DC subtypes did not demonstrate obvious 
differences in their phenotype. They were positive for the rat DC marker Ox-62, Ox-42 
(monocytes/macrophages marker) and Ox-6 (anti-MHC class II). The cell surface expression of 
costimulatory molecules (demonstrated by the failure to stain with CTLA-4Ig fusion protein) on 
immature BM-DCs was lower than on mature S-DCs which confirms the immature phenotype of 
BM-DCs. The open curves represent the background staining and the numbers on the top of the 
histograms indicate the mean fluorescence intensity of different surface molecules (for more 
details see Table 10.2 in the appendix). The results shown are representative for four flow 
cytometric analysis. 
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4.2.2 The immunohistochemistry demonstrates bone marrow-derived 
dendritic cells positive for MHC class II molecules 
The monoclonal antibodies Ox-62, Ox-6, and ED1 (macrophage marker) were 
tested. Most of the cells (> 95%) were positive for the rat DC marker Ox-62 
(Figure 4.10). High numbers of enlarged cells with an irregular shape were 
visible all of them being positive for MHC class II (Ox-6).  
 
Cytospins of purified day 6 IL-4 DCs and IL-10 DCs were stained with CTLA-4Ig 
fusion protein to prove the surface expression of CD80 and CD86. More than 
95% of the immature DCs demonstrated sometimes a low rate of surface 
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expression for these costimulatory molecules (results not shown). It seems that 
they have a mixed phenotype at this stage of development (day 6). This was 
similar for IL-4 DCs as well as for IL-10 DCs.  
 
 
Figure 4.10: Cytospin preparations of IL-4 DCs from day 6 of culture. (A) Negative control, 
(B) Ox-62, (C) Ox-6, (D) CTLA-4Ig. The staining is representative for four independent 
experiments. Magnification: x200 using an Olympus BX 50 microscope. Images were captured 
using a digital camera and processed with Corel Photo-Paint 11.  
 
 
A B
C D
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4.3 The RT-PCR analysis of bone marrow-derived dendritic cells 
demonstrates specific mRNA for MHC class II molecules, costimula-
tory molecules, and interleukin-10 
Since the low expression of costimulatory molecules is considered a sign for the 
immaturity of the dendritic cells, the expression of mRNA for the costimulatory 
molecules CD80, CD86 and CD40 was also investigated (Figure 4.11). The 
results demonstrate that immature BM-DCs were positive for these mRNAs. 
However, as shown in Figure 4.9 the bone marrow-derived dendritic cells did not 
demonstrate a strong surface expression of these costimulatory molecules.  
 
It was also investigated whether IL-4 DCs and IL-10 DCs produced different 
cytokines which allow them to modulate the T cell response (Figure 4.8). 
Interleukin-12, for instance, which plays an important role in the allograft 
rejection, is able to direct the immune response towards a Th1 phenotype both 
in vitro and in vivo.  
 
The RT-PCR analysis demonstrates that freshly isolated IL-4 DCs and IL-10 
DCs did not express mRNA for IL-12 in contrast to the mature S-DCs. 
Interleukin-10 is another important cytokine with a suppressive effect on 
activated T cells as well as on the development of mature antigen-presenting 
cells. Both subtypes of BM-DCs expressed IL-10 mRNA (see Table 10.3 in the 
appendix). The cytokine production of LPS-treated DCs is shown in Figure 4.8. 
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Figure 4.11: RT-PCR analysis of IL-4 DCs and IL-10 DCs. Mature splenic DCs (S-DCs) were 
used as controls. All three cell subsets expressed mRNA for MHC class II and the costimulatory 
molecules CD40, CD80, and CD86. The S-DCs were positive for IL-12 mRNA (see the 
appendix also). The presented results are from a single experiment but they are representative 
for five different experiments that were performed. Additional information regarding the PCR 
products can be found in chapter Materials and Methods (Table 3.4). For more details see 
Table 10.3 in the appendix. 
 
 
In addition to the qualitative proof of 
MHC class II mRNA, a quantification 
step was performed. The real time 
RT-PCR quantification showed com-
parable levels of specific mRNA for 
MHC class II between mature S-DCs 
and immature BM-DCs (Figure 4.12). 
The levels of copies in the mature S-
DCs were approx. 0.317 ± 0.105 
0
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Figure 4.12: The real time RT-PCR quanti-
fication of MHC class II. Results (mean ± 
standard deviation) from 3 different experiments 
are shown. 
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million copies. The same levels were also found for IL-4 DCs (0.410 ± 0.106 
million copies) and IL-10 DCs (0.366 ± 0.107 million copies). With 0.018 ± 
0.0003 million copies freshly isolated bone-marrow cells did not express MHC 
class II (not shown). 
 
 
4.4 Bone marrow-derived immature dendritc cells take up antigen 
The ability of the immature BM-DCs to take up antigen was assessed using 
fluorescein-isothyocyanate (FITC) conjugated Dextran. The FITC-Dextran 
incorporation was tested at different time points by flow cytometry. Purified IL-4 
DCs and IL-10 DCs from day 6 of culture were incubated with FITC-conjugated 
Dextran for 6 and 16 hours. The analysis showed an increased FITC-Dextran 
uptake depending on the length of incubation time (Figure 4.13). Formalin-fixed 
BM-DCs were used as negative control to exclude the possibility that FITC-
Dextran binds at the cell surface.  
 
 
Figure 4.13: The flow cytometric analysis of the uptake of FITC-conjugated Dextran. Both 
IL-4 DCs and IL-10 DCs were able to internalize antigens in a time-dependent manner (left 
side). The cells incubated with FITC-conjugated Dextran were measured after 6 and 16 hours. 
Formalin-fixed BM-DCs were used as negative controls (right side). They were not able to 
incorporate FITC-conjugated Dextran. Both, IL-4 DCs and IL-10 DCs were tested for their 
endocytosis capacity and the data shown here are representative for three different experiments 
with IL-4 DCs (IL-10 DCs showed similar effects).  
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Figure 4.14: The effect of IL-4 and IL-10 
DCs on the T cell proliferation. Both sub-
sets were unable to activate either naïve T 
cells in the mixed leukocytes culture (A) or 
antigen-specific T cells in the T cell 
proliferation assay (B). Naïve T cells and 
antigen-specific T cells alone were used as 
controls (1,300 ± 200 cpm). The incubation of 
S-DCs with CTLA-4Ig fusion protein (4 µg per 
104 S-DCs) inhibited the restimulation of 
antigen-specific T cells (C). The results (mean 
± standard deviation) shown are represen-
tative for 4 experiments. Control: T cells cul-
tured without DC. 
4.5 Bone marrow-derived immature dendritic cells are weak stimulators 
for T cells 
The ability of IL-4 and IL-10 DCs to activate naïve T cells was tested in the 
mixed leukocyte culture (MLC), an in vitro assay used to estimate the strength 
of the direct pathway of allorecognition (Figure 1.1). Naïve T cells from the 
popliteal lymph nodes of Wistar Furth rats did not proliferate in the presence of 
IL-4 DCs and IL-10 DCs as stimulator cells (Figure 4.14 A). The measured 
proliferation rates were 3,000 ± 500 cpm for IL-4 DCs and 2,600 ± 300 cpm for 
IL-10 DCs. In contrast, mature S-DCs induced a strong proliferation of naïve T 
cells from Wistar Furth, up to 27,000 ± 2,500 cpm. The same inabillity of IL-4 
DCs and IL-10 DCs was observed for the restimulation of antigen-specific T 
cells in the T cell proliferation assay, an in vitro assay used to evaluate the 
potency of the indirect pathway of alloantigen recognition (Figure 1.1).  
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In addition, the mature S-DCs incubated with CTLA-4Ig fusion protein failed as 
stimulators of the proliferation assay (Figure 4.14 C). This indicates the 
importance of costimulation mediated by CD80 and CD86 molecules.  
 
 
4.6 Characterization of the inhibitory effect of bone marrow-derived 
immature dendritic cells 
4.6.1 The inhibitory effect of IL-4 DCs and IL-10 DCs on T cell proli-
feration is not prevented by IL-2 
Exogenous IL-2 was able to increase dramatically the proliferation of antigen-
specific T cells in the proliferation assay up to 50,500 ± 4,500 cpm in a 
concentration-dependent manner as shown in Table 4.4 and Figure 4.15. The 
exogenous IL-2 was also able to increase the autostimulation of P1-specific T 
cells (up to 28,000 ± 6,600 cpm). The autostimulation is a phenomenon which is 
characterized by the ability of activated T cells to express MHC class II and, 
therefore, to present peptides within those molecules (see also page 27). The 
addition of IL-2 delivers a supplementary activation signal to these T cells and 
should increase their proliferation. In contrast, this stimulatory effect of IL-2 was 
very low when the P1-specific T cells were cultured with IL-4 DCs and IL-10 
DCs (Table 4.4 and Figure 4.15).  
 
Table 4.4: IL-2-dependent T cell proliferation in dependence of the DC subset used. The 
addition of IL-2 to antigen (P1)-specific T cells increased their proliferation rates in a concen-
tration-dependent manner whether they were incubated with P1-loaded S-DC or not. In 
contrast, the addition of IL-2 to the cultures of P1-specific T cells with P1-loaded IL-4 DCs or IL-
10 DCs did not increase the T cell proliferation (see also Figure 4.15). 
 IL-2 concentration (ng/ml) 
DC subset 0  133  266  
∅  3,100 ± 100 *)  22,800 ± 7,900   28,000 ± 6,600  
S-DCs **) 
 25,000 ± 2,500   40,000 ± 3,400   50,500 ± 4,500  
IL-4 DCs **) 
 3,100 ± 100   3,200 ± 500   3,500 ± 600  
IL-10 DCs **) 
 2,600 ± 300   2,900 ± 800   4,100 ± 750  
*
)
 Results (mean ± standard deviation) of T cell proliferation in cpm.  
**
)
 Loaded with peptide P1.  
∅ No DCs, P1-specific T cells were cultured in the presence of P1 without DCs. 
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Figure 4.15: IL-2 dependent T cell proliferation. The addition of IL-2 to P1-specific T cells 
alone (autostimulation) or to the T cell proliferation assay induced an increased T cell 
proliferation (diagram on the left). Exogenous IL-2 in different concentrations did not increase 
the antigen-specific T cell proliferation when these T cells were incubated with IL-4 DCs or IL-10 
DCs. The diagram on the right shows the results for IL-4 DCs (IL-10 DCs showed the same 
effect). The results (mean ± standard deviation) are representative for 3 different experiments. 
(∅) = without IL-2 and (+) = 133 ng/ml IL-2. The values are shown in Table 4.4. 
 
 
4.6.2 The supernatants from IL-4 DCs and IL-10 DCs inhibit the proli-
feration of antigen-specific T cells 
The effect of supernatant from IL-4 DCs and IL-10 DCs on the T cell 
proliferation was tested in order to investigate the presence of soluble factors 
with a suppressive potential secreted by immature DCs. For this, purified 
immature DCs from day 6 of culture were transferred to 96-well culture plates 
(104 cells/well) and cultured without the addition of any cytokines in order to 
avoid their possible influence on the T cell proliferation. Twenty-four hours later, 
the supernatant from these cultures was gently collected and transferred in 
different volumes (10 µl, 25 µl, and 50 µl) to the proliferation assay (Table 4.5 
and Figure 4.16). The final volume was kept constant at 150 µl per well in each 
experiment. The results showed clearly a dose-dependent reduction of the T 
cell proliferation when supernatant from IL-4 DCs and IL-10 DCs was 
transferred. This effect was not observed when supernatant from cultures with 
S-DCs was tested (Table 4.5). 
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Table 4.5: The supernatant from IL-4 DCs and IL-10 DCs inhibited the antigen-specific T 
cell proliferation in the proliferation assay.1) The strength of inhibition was increased with the 
volume of transferred supernatant. As control ("zero volume") 50 µl from cultures of S-DCs were 
used in order to test possible negative effects of day 2 supernatant, e.g. the exhaustion of 
essential nutrition components may influence the T cell proliferation. The results (median ± 
standard deviation) from 4 experiments for IL-4 respectively for IL-10 DCs are shown in the 
table (see also Figure 4.16). 
 Volume of supernatant (µl) *) 
 10 25 50 0 
 IL-4 DCs 
 11,000 ± 1,000 **) 5,700 ± 1,400 3,100 ± 900 
 IL-10 DCs 
 15,400 ± 800 8,600 ± 2,000 4,600 ± 900 
35,200 ± 5,100 
1)
 P1-specific T cells were incubated with P1-loaded S-DCs. 
*
)
 The final volume was kept constant at 150 µl per well. 
**
)
 Results (mean ± standard deviation) of T cell proliferation in cpm. 
 
 
Figure 4.16: The inhibitory effect of supernatant from cultures of IL-4 DCs and IL-10 DCs. 
Supernatant from both IL-4 and IL-10 DCs was able to reduce the T cell proliferation in a 
concentration-dependent manner. For this, different volumes of supernatant were transferred to 
the proliferation assay. The data (mean ± standard deviation) are representative for 4 different 
experiments, for both IL-4 DCs and IL-10 DCs. (∅) 50 µl from cultures of S-DCs were added to 
the proliferation assay. The values are shown in Table 4.5. 
 
 
In the next series of experiments it was tested whether exogenous IL-2 is able 
to influence the inhibitory effect of supernatant from IL-4 DCs and IL-10 DCs in 
the T cell proliferation assay. As shown in Table 4.6 and Figure 4.17 different 
concentrations of IL-2 were not able to compensate the inhibitory effect 
transferred with the supernatant from IL-4 DCs or from IL-10 DCs. 
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Table 4.6: The effect of exogenous IL-2 on the suppressive effect of supernatant from IL-
4 DCs and IL-10 DCs. The inhibitory effect of supernatant from IL-4 DCs on the proliferation of 
antigen-specific T cells was not reversed by the addition of exogenous IL-2. In contrast, the 
inhibitory effect of supernatant from IL-10 DCs was abolished with high doses of IL-2. Addition 
of IL-2 to the cultures containing supernatant from S-DCs increased the T cell proliferation. 
 
Transferred volume of supernatant (50 µl) from DC cultures  
IL-2 (ng/ml) IL-4 DCs IL-10 DCs S-DCs 
∅  3,100 ± 900 *)  4,600 ± 900  25,000 ± 2,500 
133  2,600 ± 1,500  8,500 ± 750  40,000 ± 3,400 
266  3,500 ± 600  27,800 ± 2,000  86,200 ± 9,900  
*
)
 Results (mean ± standard deviation) of T cell proliferation in cpm. (∅) = no IL-2 was added. 
 
 
 
 
 
 
 
 
 
 
 
4.6.3 IL-4 DCs and IL-10 DCs inhibit the restimulation of antigen-specific 
T cells dependent on their number  
The inhibitory effect of BM-DCs on the restimulation of antigen-specific T cells 
(Figure 4.14 B) was analysed in more detail. For this, the effect of different 
numbers of IL-4 DCs and IL-10 DCs on the T cell proliferation was tested (Table 
4.7 and Figure 4.18). The inhibitory effect was dependent on the number of BM-
DCs transferred to the culture. The proliferation of P1-specific T cells in the 
presence of P1-pulsed S-DCs was 35,200 ± 5,100 cpm. The addition of 103 IL-4 
DCs or IL-10 DCs to 104 mature S-DCs reduced the T cell proliferation and 105 
IL-4 DCs or IL-10 DCs totally inhibited the proliferation of P1-T cells.  
Figure 4.17: The effect of exogenous IL-2 
on the suppressive effect of supernatant 
from IL-4 DCs and IL-10 DCs. Exogenous IL-
2 was not able to induce the proliferation of 
antigen-specific T cells in the presence of 
supernatant from IL-4 DCs. In contrast, the 
proliferation was reconstituted in those wells 
containing supernatant from IL-10 DCs
combined with 266 ng/ml IL-2. This proli-
feration was similar to control wells with 
supernatant from S-DCs and 133 ng/ml IL-2. 
The results (mean ± standard deviation) are 
representative for 3 different experiments. The 
values are shown in Table 4.6. 
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Table 4.7: The inhibitory effect of IL-4 DCs and IL-10 DCs is dependent on their cell 
number. Different numbers of IL-4 DCs and IL-10 DCs were transferred to the proliferation 
assay as described in “Materials and Methods” (3.8). Both subtypes of BM-DCs inhibited the T 
cell proliferation dependent on their number. (∅) = no BM-DCs were present in the proliferation 
assays (see also Figure 4.18).  
 Number of BM-DCs 
 103 104 105 ∅ 
Ratio BM-DCs:S-DCs 1:10 1:1 10:1 ---- 
 IL-4 DCs 24,600 ± 4,500 *) 21,000 ± 2,600  3,200 ± 1,300  
 IL-10 DCs 26,900 ± 5,000  13,100 ± 1,500  2,000 ± 500  
35,200 ± 5,100 
*
)
 Results (mean ± standard deviation) of T cell proliferation in cpm. 
 
 
Figure 4.18: The inhibitory effect of IL-4 DCs and IL-10 DCs is dependent on their cell 
number. Different numbers of IL-4 DCs (left) or IL-10 DCs (right) influenced the strength of T 
cell proliferation when added to the cultures of 104 S-DCs and 105 antigen-specifc T cells. 104 
IL-10 DCs seem to be more powerful in suppressing the T cell proliferation than 104 IL-4 DCs. 
The results (mean ± standard deviation) are representative for 3 different experiments. The 
values are shown in Table 4.4 (see also the commentary in the appendix). 
 
 
4.6.4 IL-4 DCs and IL-10 DCs mediate a fast inhibitory effect  
For understanding the next set of experiments it is necessary to know the 
proliferation rates in the T cell proliferation assay at different time points. After 1 
day: below 10,000 cpm, after 2 days: 32,000 ± 5,000 cpm and after 3 days: 
70,900 ± 11,000 cpm. The effect of the addition of different numbers of 
immature DCs to the proliferation assay at different time points was tested 
(Table 4.8 and Figure 4.19). Immature bone marrow-derived dendritic cells were 
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added to the cultures between day 0 (the starting point of the culture) and day 3 
(the end of the culture). Subsequently, the cells were pulsed with [3H]-thymidine 
on day 3. In contrast to the uninfluenced proliferation rate on day 2 (32,000 ± 
5,000 cpm; see above) no incorporation was measured under these conditions 
(Table 4.8 and Figure 4.19). The reason for this is that the addition of immature 
BM-DCs to the proliferation assay on day 2 immediately inhibited the T cell 
proliferation and therefore, the “arrested” (non-proliferating) T cells could not 
incorporate [3H]-thymidine when pulsed subsequently on day 3. This is the 
reason why no proliferation could be measured on day 3. 
 
Table 4.8: The correlation between the T cell proliferation and the time point of addition 
of DCs. The addition of BM-DCs to the proliferation assay at different time points (day 0, 1, 2) 
was able to block the proliferation of antigen-specific T cells. For this, different times of cell 
addition were proved. All plates were pulsed on day 3 as described in material and methods. 
The results are representative for a set of 3 experiments for each dendritic cell type (see also 
Figure 4.19). 
 
Day of addition 
 
0 1 2 
 IL-4 DCs  1,037 ± 610 *)  900 ± 400   1,500 ± 300  
 IL-10 DCs  1,130 ± 400  1,500 ± 100   1,700 ± 400  
*
)
 Results (mean ± standard deviation) of T cell proliferation in cpm. 
 
Figure 4.19: Immature BM-DCs inhibited the antigen-specific T cell proliferation. No 
incorporation of [3H]-thymidine was measured when IL-4 DCs and IL-10 DCs were added to the 
proliferation assay on day 0, 1 or 2. The cells were pulsed on day 3 as described in "Materials 
and Methods". The values are shown in Table 4.8. In contrast, a high rate of T cell proliferation 
was measured on day 2 (32,000 ± 5,000 cpm) and 3 (70,900 ± 11,000 cpm) in the presence of 
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P1-pulsed S-DCs. The control cultures were set up without BM-DCs (∅ IL-4 DCs or ∅ IL-10 
DCs). The results (mean ± standard deviation) are representative for 3 different experiments 
(see also the commentary in the appendix). 
 
 
For the next set of experiments, the time point where the cells were pulsed with 
[3H]-thymidine was modified in order to determine the strength of T cell 
proliferation before the immature BM-DCs were added to the cultures. As 
described above, the presence of BM-DCs completely inhibited the cell division 
of activated T cells between day 2 and 3 and therefore, the incorporation of 
[3H]-thymidine was not possible. In order to measure the real level of T cell 
proliferation before the addition of BM-DCs, the procedure of [3H]-thymidine 
pulsing was modified so that the T cells were pulsed on day 2, 6 hours before 
the immature BM-DCs were added to the cultures (Table 4.10 and Figure 4.20). 
The incorporated radioactivity was measured at the end of culture on day 3. The 
results showed indeed an antigen-specific T cell proliferation until day 2 (15,500 
± 1,500 cpm for IL-4 DCs and 17,000 ± 2,000 cpm for IL-10 DCs) before 104 
immature BM-DCs were added. The addition of immature DCs suppressed the 
heavy increase of T cell proliferation between day 2 and day 3 observed in the 
normal proliferation assay. These results demonstrate the quick inhibitory effect 
mediated by IL-4 DCs and IL-10 DCs. 
 
 
Table 4.10: Immature BM-DCs inhibited immediately the antigen-specific T cell proli-
feration. The modified pulsing protocol (see text) showed that the antigen-specific T cells 
proliferated until the BM-DCs were added to the culture. The addition of 103 or 104 IL-4 DCs or 
IL-10 DCs to the proliferation assay on day 2 suppressed the increase of T cell proliferation 
observed in the uninfluenced T cell proliferation assay (Figure 4.20). The results (mean ± 
standard deviation) are representative for a series of 3 experiments for each type of BM-DCs. 
 Number of BM-DCs 
 103 104 
 IL-4 DCs  31,000 ± 3,200 *)  15,500 ± 1,500 
 IL-10 DCs  32,000 ± 5,300  17,000 ± 2,000 
*
)
 Results (mean ± standard deviation) of T cell proliferation in cpm. 
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Figure 4.20: Immature BM-DCs inhibited immediately the antigen-specific T cell proli-
feration. The addition of 104 IL-4 DCs or 104 IL-10 DCs to the proliferation assay on day 2 
suppressed the extremely strong increase in T cell proliferation between day 2 (25,000 ± 3,200 
cpm) and day 3 (100,000 ± 10,000 cpm) in the normal proliferation assay (grey columns). The 
same effect was also observed when 103 IL-4 DCs or 103 IL-10 DCs were added to the cultures 
on day 2. For these experiments the modified pulsing protocol was used (see page 43) The 
results (mean ± standard deviation) are representative for 3 different experiments. The values 
are shown in Table 4.10. 
 
 
4.6.5 The incubation of P1-specific T cells with IL-4 DCs and IL-10 DCs 
induces an anergic state  
Hundred thousand P1-specific T cells were incubated with 104 P1-pulsed IL-4 
DCs and 104 IL-10 DCs for 72 hours. Afterwards, the DCs were depleted with 
the antibody Ox-42 and magnetic-beads and the resulting T cells (= DC-Ts) 
were transferred to the second culture consisting of 104 P1-pulsed mature S-
DCs per well (Figure 4.21). After 72 hours the T cell proliferation was 
determined. The level of [3H]-thymidine incorporation was 1,700 ± 560 cpm in 
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the case of IL-4 DC-Ts and 6,600 ± 1,000 cpm in the case of IL-10 DC-Ts. This 
demonstrates that P1-pulsed S-DCs are not able to induce the restimulation of 
T cells pre-incubated with BM-DCs (termed as IL-4 DC-Ts or IL-10 DC-Ts). In 
contrast, a very strong proliferation was found in the second cultures when 
antigen-specific T cells, which were not incubated with BM-DCs during the first 
culture, were pulsed with P1 (22,100 ± 3,400 cpm) (autostimulation) or 
incubated with P1-pulsed S-DCs (39,800 ± 4,200 cpm) during the first culture 
(Figure 4.21).  
 
 
 
 
 
 
 
 
Figure 4.21: Antigen-specific T cells pre-incubated with IL-4 DCs and IL-10 DCs (first 
culture) did proliferate in the presence of P1-pulsed S-DCs after addition of IL-2. Antigen-
specific T cells were pre-incubated with IL-4 DCs and IL-10 DCs for 72 hours (first culture). 
Afterwards, the purified T cells were transferred to P1-pulsed S-DCs (second culture) shown on 
the left side. The conditions of the first culture for the antigen-specific T cells are indicated under 
each column of the diagram: IL-4 DCs: T cells incubated with IL-4 DCs; IL-10 DCs: T cells 
incubated with IL-10 DCs; T cells alone: T cells were incubated without antigen-presenting cells; 
S-DCs: T cells incubated with mature S-DCs. The diagram on the right side: Addition of IL-2 in a 
concentration of 266 ng/ml to the second culture rescued the T cells from the non-proliferative 
state induced by the BM-DCs. The columns represent the T cell proliferation before and after 
the addition of IL-2. The results (mean ± standard deviation) are representative for 3 different 
experiments. 
 
In order to test the strength of the inhibition induced by IL-4 DCs and IL-10 DCs 
on antigen-specific T cells, exogenous IL-2 was added to the second culture. 
The results indicate that both subtypes of BM-DCs induced an anergic state in 
the antigen-specific T cells which can be reverted by the addition of exogenous 
IL-2. A concentration of IL-2 of 266 ng/ml was able to induce an increase of 
proliferation from 1,700 ± 560 cpm to 34,000 ± 9,600 cpm in the case of IL-4 
DCs and from 6,600 ± 1,000 cpm to 36,900 ± 6,800 cpm in the case of IL-10 
DCs (Figure 4.21). 
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4.6.6 P1-specific T cells incubated with IL-4 DCs but not with IL-10 DCs 
mediate an inhibitory effect 
In the previous chapter, it was shown that P1-specific T cells which were 
cultured with IL-4 DCs and IL-10 DCs did not proliferate when they were 
transferred to P1-loaded mature splenic DCs. However, this anergic-like effect 
could be reverted by adding exogenous IL-2 (Figure 4.21, right diagram). In the 
following series of experiments, these T cells (termed as DC-Ts) were tested for 
their potential to suppress the proliferation of uninfluenced P1-specific T cells 
restimulated in the proliferation assay. The DC-Ts recovered from the first 
culture with IL-4 DCs and IL-10 DCs were transferred to the T cell proliferation 
assay in different numbers (from 10 cells up to 104 cells per well). These 
cultures were incubated for 3 days and the proliferation was measured 
afterwards. The results showed that the T cells incubated with IL-4 DCs in the 
first culture (= IL-4 DC-Ts) were able to inhibit the proliferation of the P1-T cells 
in the proliferation assay depending on their number (Figure 4.22). This effect 
was not seen for the IL-10 DC-Ts which were pre-incubated with IL-10 DCs.  
 
Table 4.11: P1-specific T cells pre-incubated with IL-4 DCs had an inhibitory effect on T 
cell proliferation. These IL-4 DC-Ts were able to inhibit the proliferation of antigen-specific T 
cells in the proliferation assay depending on the added cell number. The transfer of T cells pre-
incubated with IL-10 DCs (= IL-10 DC-Ts) had no effect irrespective of how many cells were 
transferred (see also Figure 4.22). 
Number of IL-4 DC-Ts transferred to the proliferation assay *) 
103 104 105 
36,500 ± 4,600 **) 23,600 ± 8,700 5,900 ± 3,300 
Number of IL-10 DC-Ts transferred transferred to the proliferation assay *) 
103 104 105 
41,000 ± 9,500 **) 43,900 ± 8,000 40,000 ± 9,600 
*
)
 IL-4 DC-Ts: pre-incubated with IL-4 DCs; IL-10 DC-Ts: pre-incubated with IL-10 DCs. 
**
)
 Results (mean ± standard deviation) of T cell proliferation in cpm. 
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Figure 4.22: P1-specific T cells incubated with IL-4 DCs but not with IL-10 DCs seem to 
mediate an inhibitory effect on the proliferation of antigen-specific T cells. P1-specific T 
cells were pre-incubated for 72 hours with P1-pulsed IL-4 DCs or IL-10 DCs. Afterwards, the 
dendritic cells were depleted and the purified T cells were transferred to a second culture, the T 
cell proliferation assay consisted of P1-pulsed S-DCs and antigen-specific T cells as described 
in “Materials and Methods”. The inhibitory effect of IL-4 DC-Ts (antigen-specific T cells which 
were incubated with IL-4 DCs) was dependent on the number of transferred cells (left diagram 
and Table 4.11). In contrast, IL-10 DC-Ts (T cells which were pre-incubated with IL-10 DCs 
were not able to influence the proliferation of P1-T cells in the proliferation assay. The results 
(mean ± standard deviation) from 3 different experiments (each for IL-4 DC-Ts and IL-10 DC-
Ts) are shown. DC-T cells: P1-specific T cells pre-incubated with the appropriate BM-DCs; P1-T 
cells: P1-specific T cells freshly isolated from P1-immunized Lewis rats.  
 
 
In order to estimate whether the effect of IL-4 DCs on antigen-specific T cells 
will be impaired when they are separated by a membrane, both cell subsets 
were cultured in transwell plates from Greiner bio-one, Germany (Figure 4.23). 
The P1-pulsed IL-4 DCs were incubated in the upper chambers (the transwell 
insert) and the P1-T cells in the lower compartment. Direct contact between the 
IL-4 DCs and the T cells was avoided by a membrane with a pore size of 0.4 
µm. After 3 days the T cells (= IL-4 DC-Ts) were transferred to the proliferation 
assay or second culture. The unaffected T cell proliferation in the second 
culture was 102,500 ± 15,500 cpm. However, the IL-4 DC-Ts, which were 
separated by a membrane from the IL-4 DCs during the first culture, did not 
show any inhibitory effects on the T cell proliferation even at high numbers 
(Table 4.12).  
 
These results demonstrate that the direct contact between the IL-4 DCs and the 
antigen-specific T cells in the first culture is absolutely necessary in order to 
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induce regulatory properties in these T cells. However, these experiments could 
not elucidate whether the IL-4 DCs mediated their inhibitory effect through a 
soluble factor small enough to pass the membrane. 
 
Table 4.12: IL-4 DC-Ts needed the direct contact with IL-4 DCs to demonstrate an 
inhibitory effect. The transfer of antigen-specific T cells pre-incubated with IL-4 DCs (= IL-4 
DC-Ts) in transwell plates had no effect on the proliferation of antigen-specific T cells in the 
proliferation assay (see also Figure 4.23). In contrast, antigen-specific T cells pre-incubated 
with IL-4 DCs (= IL-4 DC-Ts) without separation by a membrane demonstrated an effect on the 
proliferation of antigen-specific T cells (Table 4.11). 
 
Number of transferred IL-4 DC-Ts 
 
102 103 104 105 
T cell proliferation 116,000 ± 11,000 *) 127,000 ± 12,000  128,000 ± 14,000  111,000 ± 8,000  
*
)
 Results (mean ± standard deviation) of T cell proliferation in cpm. 
 
*
)
 The proliferation assay consists of 104 P1-loaded S-DCs and 105 P1-specific T cells. 
#)
 The values are shown in Table 4.12. 
 
 
4.7. The in vivo effects of bone marrow-derived immature dendritic cells 
Seven days after subcutaneous immunization with the immunogeneic peptide 
P1, the popliteal lymph nodes were enlarged (Figure 4.24) and the cell number 
increased from 3.3 x 107 ± 1.4 x 107 in non-immunized animals to 12.3 x 107 ± 
2.7 x 107 in P1-immunized animals (not shown).  
Figure 4.23: IL-4 DC-Ts needed the direct 
contact with IL-4 DCs to demonstrate an 
inhibitory effect. In the first culture the T 
cells were incubated in the upper chamber of 
a transwell plate. IL-4 DCs were pulsed with 
P1 and cultured in the lower chamber of the 
same transwell plate. After 72 hours the T 
cells from the first culture (IL-4 DC-Ts or IL-10 
DC-Ts were transferred to a second culture or
proliferation assay *) and incubated for 
another 72 hours. No inhibitory effect of the 
transferred cells was observed. The results 
(mean ± standard deviation) are representa-
tive for 3 different experiments.#) 
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The next set of experiments with IL-4 DCs and IL-10 DCs were performed in 
vivo in order to clarify whether these cells are able to influence the local immune 
response. Therefore, the effect of P1-pulsed S-DCs was compared to the effect 
mediated by IL-4 DCs and IL-10 DCs, respectively. The cells were injected 
subcutaneously into the hind foot pad of naïve Lewis rats (Figure 4.24). Peptide 
P1 mixed with the adjuvant TiterMax were used as control. The popliteal lymph 
nodes were collected 7 days after injection and the isolated lymphocytes were 
tested in the proliferation assay. The immunization with P1 induced a strong 
local immune response as indicated by the enlarged lymph nodes (Figure 4.24) 
and an increased T cell proliferation (90,000 ± 8,900 cpm) (Figure 4.25). The 
same T cell proliferation was observed after the injection of P1-loaded S-DCs 
(81,000 ± 8,900 cpm). In contrast, P1-loaded IL-4 DCs caused a decreased T 
cell proliferation of 33,900 ± 4,600 cpm (Figure 4.14B). P1-loaded IL-10 DCs 
induced an increased T cell proliferation of 70,900 ± 11,000 cpm (Figure 4.14B). 
From the results in vitro (Figure 4.14) it was expected that both types of BMDCs 
prevent the induction of antigen-specific T cells in the local lymph nodes (see 
also appendix).  
 
Figure 4.24: The subcutaneous immunization with peptide P1 and TiterMax lead to a 
strong local immune response. This immune activation is not obviously reflected in swelling of 
the foot pad (A; left: non-immunized, right: immunized) but in the enlarged popliteal lymph 
nodes. They increased from 1-2 mm in non-immunized animals to 6-7 mm in P1-immunized 
animals (B). The immunization with TiterMax did not enlarge significantly the lymph nodes (2-3 
mm). The distance between the lines represents 1 mm. 
A B
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The level of non-stimulated antigen-specific T cell proliferation was 17,900 ± 2,000 cpm (not 
shown). 
 
The main question remained whether P1-loaded immature DCs influenced the 
survival time of Wistar Furth allografts in Lewis rats (Figure 3.1). Therefore, P1-
loaded IL-4 DCs and IL-10 DCs were transferred into Lewis rats 7 days or 1 day 
prior to transplantation of a Wistar Furth heart (see also Figure 10.1 in the 
appendix). Peptide P1 led to an accelerated rejection of Wistar Furth allografts 
but not of syngeneic Lewis grafts (Table 4.13, groups 2 and 4). 
 
 
Table 4.13: The immunization of Lewis rats with the allogeneic peptide P1 seven days 
before transplantation influence the survival of heart allografts from Wistar Furth donors. 
In the allogeneic control (Ctr) group, Lewis rats were not immunized with P1. Untreated Lewis 
rats in the syngeneic control (Ctr) group and P1-immunized Lewis rats in group 4 received 
syngeneic heart grafts. The immunization was performed 7 days before transplantation. 
Group #) Graft survival (days) MST ± SD (days) #,#) n 
1 Allogeneic Ctr  7 (x4), 8 (x2)  7.3 ± 0.5 6 
2 Allogeneic Ctr + P1 *)  5 (x2), 6  5.2 ± 0.4 3 
3 Syngeneic Ctr **)  > 50 (x3)  > 50 3 
4 Syngeneic Ctr + P1 *) **)  > 50 (x3)  > 50 3 
 
      
#)
 Direction of transplantation: Group 1: Wistar Furth → Lewis 
 Group 2: Wistar Furth → P1-immunized Lewis 
 Group 3: Lewis → Lewis  
 Group 4: Lewis → P1-immunized Lewis 
#,#)
 MST: mean survival time; SD: standard deviation. 
*) Peptide P1 was mixed with TiterMax before injection. TiterMax does not influence the 
survival time of heart allografts: 7.7 ± 0.6 days (n=3); (single time points: 7 (x1), 8 (x2)). 
**)
 The syngeneic transplantation led to indefinite graft survival (> 100 days); here the ex-
periments were regularly terminated on day 50 p. op. 
Figure 4.25: Subcutaneous immunization 
with P1 lead to a strong proliferation of T 
cells isolated from the popliteal lymph 
nodes. Seven days after immunization the 
isolated lymphocytes were tested in the 
proliferation assay with P1-loaded S-DCs. P1-
loaded S-DCs or P1-loaded IL-10 DCs led to 
a similar reaction in the local lymph node. P1-
loaded IL-4 DCs induced a weaker local 
immune response. The results are 
representative for 3 different experiments for 
each immunization procedure.  
 
0
20
40
60
80
100
T 
ce
llp
ro
life
ra
tio
n
(x 
10
3
cp
m
)
1x104 DCs
1x105 P1 T cells
8.3 µg/ml P1
S-DCs+P1 IL-4 DCs+P1IL-10 DCs+P1P1
Immunization procedure
T 
ce
llp
ro
life
ra
tio
n
(x 
10
3
cp
m
)
 
 51 
For the transplantation experiments, 10 million IL-4 DCs or IL-10 DCs were 
administered intravenously 7 days or 1 day before transplantation (1 million 
cells had no effect; see Table 10.1 in the appendix). On day 0, the animals 
received a heart allograft in a heterotopic position and the allograft survival was 
estimated by palpation of the heart beating (Figure 3.1). The transfer of P1-
loaded BM-DCs one day before transplantation led to better results than the cell 
transfer 7 days before transplantation (Table 4.14 groups 6-9). Both IL-4 DCs 
and IL-10 DCs seem to have a slight protective effect on the allograft function. 
They prolonged the survival time for two days without immunosuppression in 
comparison to the allogeneic control group (Table 4.13, group 1 vs. groups 8 
and 9 in Table 4.14). 
 
Table 4.14: Ten million P1-pulsed IL-4 DCs and IL-10 DCs slightly prolong the survival of 
heart allografts of Wistar Furth donors in Lewis recipients. P1-pulsed DCs and unpulsed 
control (Ctr) DCs were injected i.v. into Lewis rats 7 days (d -7) or 1 day (d -1) before the 
transplantation of WF heart grafts. Untreated Lewis rats did not receive DCs before 
transplantation. For more details see Table 10.1 in the appendix. 
Group #) Graft survival (days) MST ± SD (days) #,#) n 
5 Ctr-DC (d -7, d -1) *)  6, 7 (x6), 8  7.0 ± 0.8 8 
6 IL-4 DC + P1 (d -7) **)  7 (x2), 8 (x4), 9  7.9 ± 0.7 7 
7 IL-10 DC + P1 (d -7) **)  7 (x2), 9 (x3)  8.2 ± 1.1 5 
8 IL-4 DC + P1 (d -1) **)  9 (x3), 11  9.5 ± 1.0 4 
9 IL-10 DC + P1 (d -1) **)  8, 9 (x2), 10 (x5)  9.5 ± 0.8 8 
 
      
#)
 Direction of transplantation: Wistar Furth → Lewis. 
#,#)
 MST: mean survival time; SD: standard deviation. 
*)  Unpulsed IL-4 and IL-10 DC were used as controls (n=4 for each DC subtype. 
**)
 Ten Million DCs were loaded with 20 µg P1 in a total volume of 500 µl PBS for 30 minutes at 
4°C. 
 
 
In order to prove the antigen specificity of P1-pulsed immature BM-DC in 
prolongation of WF allografts, their effect on third party allografts was 
measured. For this, Brown Norway (BN) rats were used as third party donors. 
Again, P1-loaded IL-4 or IL-10 DCs were transferred intravenously into Lewis 
rats one day before transplantation. As shown in Table 10.1 (in the appendix) 
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heart allografts from Brown Norway donors were not protected by the 
administration of P1-loaded BM-DCs. This indicates that the prolongation of WF 
allograft survival induced by P1-pulsed BM-DCs is, indeed, an antigen-specific 
effect manifest only for Wistar Furth allografts.  
 
Table 4.15: Ten million P1-pulsed IL-10 DCs do not influence the survival of heart 
allografts from third party donors (Brown Norway rats). The P1-pulsed IL-10 DCs were 
injected i.v. one day (d -1) before transplantation. The recipients in the untreated controls were 
not infused with DCs. For more detail see Table 10.1 in the appendix. 
Group #) Graft survival (days) MST ± SD (days) #,#) n 
10 Untreated  7 (x3)  7.0 ± 0.0 3 
11 IL-10 DC + P1 (d -1) *)  7 (x3)  7.0 ± 0.0 3 
 
      
#)
 Direction of transplantation: BN → Lewis. 
#,#)
 MST: mean survival time; SD: standard deviation. 
*
)
 Ten million DCs were loaded with 20 µg P1 in a total volume of 500 µl PBS for 30 minutes at 
4°C. 
 
 
To prove whether the effect of P1-pulsed IL-10 DCs could be enhanced, the 
amount of transferred DCs was increased to 30 million cells. As demonstrated 
in Table 4.16 (group 12) the protective effect was increased and the allograft 
survival was prolonged to day 10 (Table 4.16). The effect of 30 million P1-pulsed 
IL-4 DCs will be tested, too. 
 
 
Table 4.16: Thirty million P1-pulsed IL-10 DCs prolong the survival of heart allografts of 
Wistar Furth donors in Lewis recipients (group 12). 
Group #) Graft survival (days) MST ± SD (days) #,#) n 
1 Allogeneic Ctr *)  7 (x4), 8 (x2)  7.3 ± 0.5 6 
9 IL-10 DC + P1 (d -1) *)  8, 9 (x2), 10 (x5)  9.5 ± 0.8 8 
12 IL-10 DC + P1 (d -1) **)  10 (x3), 11 (x2), 12  10.6 ± 0.8 6 
 
      
#)
 Direction of transplantation: Wistar Furth → Lewis. 
#,#)
 MST: mean survival time; SD: standard deviation. 
*)  See tables 4.12 and 4.13. 
**)
 Thirty million DCs were loaded with 20 µg P1 in a total volume of 500 µl PBS for 30 minutes 
at 4°C. 
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5 Conclusions 
 
The present study demonstrates an immune inhibitory effect for IL-4 DCs and 
IL-10 DCs in vitro and in vivo. The results provide the answers to the following 
questions: 
 
(1) What are the main phenotypic characteristics of immature bone marrow-
derived dendritic cells? 
A homogenous population of rat immature dendritic cells was generated from 
bone marrow precursors cultured with GM-CSF and IL-4 (= IL-4 DCs) or GM-
CSF and IL-10 (= IL-10 DCs). These cells had a similar immature phenotype 
and showed no or a very low surface expression of costimulatory molecules 
such as CD80 and CD86. They also demonstrated a 10-fold reduced 
expression of MHC class II molecules on the cell surface in comparison to 
mature splenic DCs (Figure 4.9). 
 
(2) What is the effect of immature bone marrow-derived dendritic cells on naïve 
and antigen-specific T cells? 
Neither IL-4 DCs nor IL-10 DCs were able to activate naïve T cells or to 
restimulate antigen-specific T cells (Figure 4.14). This strong inhibitory effect, 
mediated within 24 hours (Figure 4.20), was dependent on the number of 
immature dendritic cells added to the proliferation assay (Figure 4.18). Antigen-
specific T cells pre-incubated with IL-4 DCs and IL-10 DCs were not able to 
proliferate in the presence of P1-pulsed S-DCs. This anergic state was 
reversible with the addition of exogenous IL-2 (Figure 4.21).  
 
(3) Do P1-pulsed immature bone marrow-derived dendritic cells influence the 
allograft survival in an antigen-specific manner? 
The in vivo results demonstrate that these cells play an important role in the 
antigen-specific prolongation of allograft survival (Tables 4.13 and 4.15). Both IL-
4 DCs and IL-10 DCs loaded with P1 were able to prolong the allograft survival 
in an antigen-specific manner. 
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6 Discussion 
 
The use of immature dendritic cells with regulatory properties for the induction 
of graft acceptance instead of chronic immunosuppression appears to be very 
attractive. However, the diversity between humans and the common animal 
models mice and rats makes the development of a "universal" protocol for 
immunomodulation difficult. Presently, rat immature dendritic cells are only 
poorly characterized. Therefore, in the present study, the morphology, pheno-
type, and tolerogenic function of rat immature bone marrow-derived dendritic 
cells were characterized. 
 
 
6.1 IL-4 or IL-10 in combination with GM-CSF influence the promotion of 
immature rat dendritic cells  
Immature rat dendritic cells (DCs) were propagated from bone marrow cells 
isolated from big bones such as femurs and tibia (Chen-Woan M et al., 1995; 
MacDonald KP et al., 2005). In the present study it was shown that a cell 
density of 5.0 x 105 bone marrow precursors per ml is ideal to generate approxi-
mately 2.5 x 106 to 5.0 x 106 bone marrow DCs per culture dish (Table 4.1). 
These findings are in accordance with the results published by Grauer (Grauer 
O et al., 2002). The experiments performed in the present study showed that 
the yield of immature dendritic cells generated from up to 30 x 106 bone marrow 
cells (isolated from two femurs) was more than sufficient for different in vitro 
assays and adoptive transfer experiments (chapter 4.7).  
 
In the present study, the rat bone marrow-derived immature dendritic cells 
generated in the presence of GM-CSF plus IL-4 were termed IL-4 DCs and 
those generated in the presence of GM-CSF plus IL-10 were termed IL-10 DCs. 
 
Both cytokine combinations, GM-CSF plus IL-4 and GM-CSF plus IL-10, 
promote the differentiation of bone marrow precursor cells into immature 
dendritic cells as confirmed in the present study. Many publications describe the 
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successful generation of immature dendritic cells with these cytokine com-
binations in different species, e.g. human, mouse and rat (Kubsch S et al., 
2003; Zheng Z et al., 2004; Lutz MB et al., 2000 [1,2]; DePaz HA et al. 2003). 
However, it is not always clearly defined how the different concentrations of 
cytokines influence the maturation state of dendritic cells in different animals. 
For example, GM-CSF (1 ng/ml and more as the final concentration) combined 
with IL-4 induces the formation of mature BM-DCs in mice (Lutz MB et al., 2000 
[1]), whereas the same combination propagates immature dendritic cells in rats 
(Garrovillo M et al., 2001).  
 
In the present study, 5 ng/ml GM-CSF combined with IL-4 (5 ng/ml) was used to 
generate immature DC. These results are opposed to the findings of other 
groups, where such high doses of GM-CSF generated potent immune stimu-
latory DCs (Lutz MB et al., 1999). The combination of GM-CSF with IL-10 was 
shown to be able to induce the formation of immature bone marrow dendritic 
cells in mice and rats (Duan RS et al., 2005).  
 
Both the phenotype and the immature state of IL-4 DCs and IL-10 DCs seem to 
be identical: the cells demonstrate a very low surface expression of costimu-
latory molecules as well as a 10-fold reduced surface expression of MHC class 
II molecules (Figure 4.9). In addition, these cells were positive for the Ox-62 
epitope, an integrin-like molecule that is characteristic for rat dendritic cells. The 
high endocytosis capacity, demonstrated by measuring the uptake of FITC-
conjugated Dextran, is another characteristic pleading for the immaturity of 
these cells. It is well known that immature dendritic cells demonstrate a high 
capacity to take up antigens but an inability to present them, whereas mature 
dendritic cells are professional antigen presenting cells with a low capacity of 
endocytosis (Hotta C et al., 2006). The immature dendritic cells recovered from 
the cell clusters of a 6-day culture (Figure 4.4) were found to be negative for the 
fibroblast marker prolyl 4-hydroxylase in contrast to the strongly adherent cells 
with a fibroblast-like shape outside the clusters (not shown). In summary, these 
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data confirm that the cells propagated in the presence of GM-CSF plus IL-4 and 
GM-CSF plus IL-10 are dendritic cells in an immature stage of development. 
 
 
6.2 The nature of the inhibitory effect mediated by immature dendritic 
cells: indications for soluble and non-soluble factors  
None of the IL-4 DCs or IL-10 DCs have the capacity to stimulate naïve T cells 
(Figure 4.14 A). This was not surprising because these cells had a low or no 
expression of the costimulatory molecules CD80 and CD86 as demonstrated by 
flow cytometry (Figure 4.9). In addition, the RT-PCR analysis showed the 
presence of mRNA for CD80, CD86 and CD40. 
 
In addition, the immature BM-DCs were also unable to restimulate antigen-
specific T cells (Figure 4.14 B). The reason for this may be the noted inability of 
these cells to fully express costimulatory molecules and, in consequence, their 
inability to deliver optimal signals to the T cells. The immune inhibitory effect 
caused by the block of costimulation was confirmed by in vitro experiments with 
the CTLA-4Ig fusion protein (Figure 4.14 C). This protein, which blocks the 
interaction between CD28 on the surface of T cells and the costimulatory 
molecules CD80 and CD86 on the surface of DCs, inhibits the stimulatory effect 
of mature DCs in the T cell proliferation assay. The block of costimulation also 
has an inhibitory effect in vivo: for example, the combined application of anti-
CD40 and anti-CD86 antibodies prolonged the allograft survival in primates 
(Haanstra KG et al., 2003; Guillot C et al., 2003; Bjorck P et al., 2005). 
 
In a further set of experiments, BM-DCs were added in different cell numbers 
(103 - 105) to the proliferation assay with constant numbers (104) of splenic DCs 
(Figure 4.18). Immature and mature splenic DCs compete for the antigen-
specific T cells and, as expected, the T cell proliferation was totally inhibited in 
the presence of high numbers of immature DCs (105 cells). In addition, the 
inhibitory effect mediated by the immature DCs was measurable within 24 hours 
(Figure 4.20). In most of the studies, immature DCs were incubated with T cells 
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for 3 or 4 days prior the proliferation rate was measured (DePaz HA et al., 
2003). However, as demonstrated in this study, these types of experiments are 
not very insightful with regard to the efficacy of immature DCs. Therefore, the 
protocol was changed and the T cells were pulsed with [3H]-Thymidine before 
the immature DCs were added. The results showed clearly that immature DCs 
dramatically inhibited the T cell proliferation within 24 hours. The effect, caused 
by already one million (103) immature IL-4 DCs, was strong enough to prevent 
the increase of T cell proliferation from 31,000 ± 3,200 cpm to 100,000 ± 10,000 
which usually occur within the last 24 hours of culture in the proliferation assay 
(Figure 4.20). 
 
Furthermore, the inhibitory effect of BM-DCs on the T cell proliferation was not 
reversible with exogenous IL-2. This result was unexpected because the 
activated T cells expressed the IL-2 receptor and, therefore, they should 
proliferate strongly in the presence of IL-2 (Figure 4.15). In addition, activated rat 
T cells expressed MHC class II molecules on their cell surface that enabled 
them to present antigens independently of dendritic cells and allowed them to 
stimulate each other (Kottenmeier S, 2005). This phenomenon, called auto-
stimulation, should also occur in the presence of such costimulation-impaired 
BM-DCs. However, as demonstrated in this study, the presence of IL-4 DCs 
and IL-10 DCs completely inhibited the autostimulation (Figure 4.6).  
 
The reduced T cell proliferation in the presence of supernatant from IL-4 DCs 
and IL-10 DCs may indicate the existence of a soluble factor. The inhibitory 
effect was dependent on the volume of transferred supernatant (Figure 4.16). 
The possibility that immature dendritic cells influence the proliferation of T cells 
by secreting a soluble factor was already described (Guillot C et al., 2003). In 
order to avoid any influence by the cytokines used for the DC culture on the T 
cell proliferation, purified dendritic cells from day 6 were cultured without 
cytokines. An anti-proliferative effect was found, when the supernatant from 
these cultures was tested. In contrast, the supernatant from mature S-DCs did 
not influence the T cell proliferation. In order to exclude the possibility that the 
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results are influenced by contaminated cells (macrophages, fibroblasts) these 
cell types were also tested for their possible effect on the T cell proliferation. 
The results showed that macrophages and fibroblasts are unable to restimulate 
antigen-specific T cells and they also do not stop the autostimulation in contrast 
to immature DCs (Figure 4.6). 
 
The effect of purified IL-4 and IL-10 on the restimulation of antigen-specific T 
cells was totally different from the inhibitory effect of supernatant from IL-4 DCs 
and IL-10 DCs: IL-4 increased the T cell proliferation, whereas IL-10 had no 
effect (Tables 10.4 and 10.5 in the appendix).  
 
In summary, these results demonstrate that immature IL-4 DCs and IL-10 DCs 
are very potent inhibitors of the activation of naïve T cells and the restimulation 
of antigen-specific T cells. The main reason for their inhibitory effect may be the 
low expression of costimulatory molecules on their cell surface. However, 
different other mechanisms such as the secretion of a soluble factor may also 
be involved (Figure 4.17). 
 
 
6.3 Immature dendritic cells are able to induce anergic T cells with 
immune inhibitory properties 
A very important question addresses the possibility of turning antigen-specific T 
cells into regulatory T cells with immune inhibitory properties (Kuwana M, 2002). 
As demonstrated in this study, P1-specific T cells did not proliferate in the 
presence of IL-4 DCs and IL-10 DCs. A further result of this interaction is that 
these T cells demonstrated an anergic state (Figure 4.21) after the incubation 
with immature DCs.  
 
For the human system, several groups have demonstrated that antigen-specific 
CD4+ T cells can be converted into an anergic state (Kuwana M et al., 2001; 
Steinbrink K et al., 2002). These cells shared similar characteristics with the so-
called type I regulatory T cells (Tr1) and they act mainly through secretion of 
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soluble factors like IL-10 and TGF-β (Bacchetta R et al., 2005). In contrast, no 
information was found in the literature∗) about the effect of rat immature 
dendritic cells on inducing antigen-specific anergy. Therefore, in the present 
study, the effect of IL-4 DCs or IL-10 DCs on P1-specific T cells was analysed 
in more detail. For this, P1-specific T cells were incubated with P1-pulsed IL-4 
DCs or IL-10 DCs for 3 days. Afterwards, the purified T cells were transferred to 
the proliferation assay consisting of P1-pulsed mature S-DCs and antigen-
specific T cells. T cells incubated with IL-4 DCs (called IL-4 DC-Ts) were able to 
inhibit the T cell proliferation in a cell number dependent manner (Figure 4.22). 
In contrast, antigen-specific T cells pre-incubated with P1-pulsed IL-10 DCs (= 
IL-10 DC-Ts) showed no effect on the proliferation assay. This was the unique 
difference between IL-4 DCs and IL-10 DCs found in the present study. The 
suppressive effect of IL-4 DC-Ts cells was confirmed in 3 independent 
experiments.  
 
The regulatory effect of anergic T cells is well known (Kuwana M. et al., 2002; 
Jonuleit H et al., 2003; Kubsch S et al., 2003; Bashuda H et al., 2005). Most of 
these studies described the necessity of a cell-cell contact between the im-
mature dendritic cells and activated T cells in order to induce anergy. The sub-
optimal presentation of the antigen in the absence of costimulation induces 
anergy. Both subsets of immature dendritic cells, the IL-4 DCs and the IL-10 
DCs, demonstrate, besides the negligible cell surface expression of co-
stimulatory molecules, a ten-fold decreased expression of MHC class II mole-
cules. The need for IL-2 in order to reactivate antigen-specific T cells after the 
incubation with IL-4 DCs and IL-10 DCs (Figure 4.21) indicate their ability to 
induce anergy in antigen-specific T cells. The experiments in the present study, 
performed in transwell chamber plates, confirmed that the contact between the 
antigen-specific T cells and the P1-pulsed IL-4 DCs is essential in order to 
induce anergy (Figure 4.23).  
 
                                                 
∗
 Medline research with the keywords: rat, antigen-specific T cells, anergy. 
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From the results presented here it is difficult to conclude whether the 
suppressive effect of IL-4 DCs or IL-10 DCs is mainly mediated by cell-cell 
contact or soluble factors. Presently, it is controversial whether soluble factors 
may be potent enough in order to influence T cell activation in an antigen-
specific manner. Therefore, the cell-cell contact mechanism is more important. 
In addition, a combination of both mechanisms may be possible. The soluble 
factor might be sufficient to mediate the direct effect of the immature DCs on the 
proliferation of antigen-specific T cells while the cell-cell contact mechanism 
might be absolutely necessary in order to induce the regulatory properties of 
these T cells. 
 
 
6.4 Immature dendritic cells and their potential to prevent allograft 
rejection 
The immature IL-4 DCs and IL-10 DCs have a series of interesting in vitro 
effects and, therefore, they were also tested in vivo. In order to modulate the 
alloimmune response specifically, the strategy should include the antigen. For 
the animal model used in the present study the antigen was the allogeneic 
peptide P1 (Figure 10.1). The main idea was to present this antigen, which 
accelerates allograft rejection, to host T cells in the absence of costimulatory 
signals in order to turn alloreactive T cells into anergic or regulatory T cells 
instead of effector T cells. The presence of MHC class II on the cell surface of 
IL-4 Dcs and IL-10 DCs allows their loading with P1. 
 
One characteristic of the in vivo situation is that it is very complex. Therefore, 
the first question was whether P1-loaded immature BM-DCs influence the local 
immune response. For this, one million P1-loaded IL-4 DCs and IL-10 DCs were 
administered subcutaneously into the foot-pad of Lewis rats. S-DCs were used 
as controls. Seven days later, lymphocytes isolated from the local lymph nodes 
were tested in the proliferation assay. Lymphocytes from animals immunized 
with P1-loaded S-DCs were sensitized and therefore showed a strong T cell 
proliferation in the proliferation assay (Figure 4.25). In contrast, after the 
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injection of P1-loaded IL-4, the T cell proliferation was strongly reduced, 
whereas the P1-loaded IL-10 DCs did not desensitize the lymphocytes in vivo. 
In this case, the T cells isolated from the local lymph nodes demonstrated a 
normal proliferation in vitro. These results showed that it is possible to influence 
the local T-cell immune response with P1-loaded dendritic cells. 
 
Further on, the efficiency of P1-pulsed IL4-DCs and IL-10 DCs to prevent 
allograft survival was proved. The cell transfer performed one day before trans-
plantation was quite efficient than the administration at day -7 (Table 4.14). The 
reason for this is presently unknown. One possible explanation could be that 
during the long time between cell transfer and transplantation the immature BM-
DCs get different maturation stimuli from the environment. The matured DCs 
are able to activate effector T cells, which decrease the allograft survival time. 
The positive effect of P1-pulsed BM-DCs on the survival time can be improved 
with an increase in the number of transferred cells. With 30 million P1-pulsed 
BM-DCs the survival time was prolonged to a median of 10.6 ± 0.8 days (Table 
4.16). 
 
For the development of an efficient antigen-specific cell therapy it is necessary 
to understand which part of the host immune response is affected by such a 
protocol. Immediately after transplantation the direct pathway of allorecognition 
(Figure 1.1) dominates the immune response. On the other hand, there is 
evidence that the indirect pathway alone is sufficient in order to induce allograft 
rejection (Game DS et al., 2002; Nouri-Shirazi M et al., 2002). Therefore, in 
order to prolong allograft survival, it is important to control both pathways (Lutz 
MB et al., 2002; Ichim TE et al., 2003; Abe M et al., 2005). The results of the 
transplantation experiments indicate that it is possible to influence the activation 
of alloreactive T cells with P1-pulsed BM-DCs (Tables 4.15 and 4.16). Another 
very important aspect is the antigen-specificity of the effect of P1-loaded BM-
DCs. This was clearly demonstrated in the present study in the transplantation 
model where P1-loaded BM-DCs had no protective effect on the survival of third 
party allografts in Lewis rats (Figure 10.1 in the appendix).  
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Rat BM-DCs can be useful to influence the alloimmune response (Table 6.1). 
The in vitro results showed an extraordinary ability of these cells to impair the 
activation of naïve T cells as well as the restimulation of antigen-specific T cells. 
The present study also demonstrated their effects in vivo. Considering the 
strength of the alloimmune response, even a slight prolongation of the allograft 
survival of 2 to 4 days is a step forward. These data clearly show that immature 
DCs influence the complete immune system of immune competent animals. 
However, the data also demonstrate the necessity to support the cell-mediated 
inhibitory effect with a short-term immunosuppression. Therefore, different 
immunosuppressive agents used in the clinic should be tested to find the best 
one for synergizing the suppressive effect of the immature DCs (Taner T et al., 
2005; Sheng Sun D et al., 2005). Beriou described an indefinite allograft 
survival for more than 100 days when they combined immature DCs with a 
suboptimal immunosuppressive treatment (Beriou G et al., 2005). In contrast, 
no immunosuppressive treatment was administered during the experiments 
described in the present study.  
 
Presently, there is no alternative to the immunosuppressive treatment, yet, 
immature dendritic cells pulsed with alloantigens seem to be promising candi-
dates for an antigen-specific therapy to eventually replace the unspecific 
chronic immunosuppression after transplantation (Jonuleit H et al., 2003; 
Schlichting CL et al., 2005).  
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Table 6.1: Properties of immature bone marrow-derived rat dendritic cells demonstrated 
in the present study. The properties for IL-4 DCs and IL-10 DCs are compared with data from 
the literature (listed in "References"). 
 IL-4 DCs IL-10 DCs  Literature 
No surface expression of CD80 and CD86 Yes Yes  Yes (1, 2) 
Reduced surface expression of MHC class II Yes Yes  Yes (1) 
Inhibition of the activation of naïve T cells Yes Yes  Yes (1) 
Inhibition of the restimulation of activated T 
cells Yes Yes  Yes (1) 
Soluble factor (s) with inhibitory properties Yes Yes  Yes (3, 4) 
Induction of T cell anergy Yes Yes  No data 
Induction of anergic T cells with regulatory 
properties 
Yes No  No data 
(1) DePaz HA et al. Transplantation 2003; 75 (4): 521-528 
(2) Karulin AY et al. J Immunol 2000; 164 (4): 1862-1872 
(3) Guillot C et al. Blood 2003; 15; 101 (8):3325-33 
(4) Powell TJ et al. Immunology 2003; 109 (2): 197-208 
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7 Summary 
 
Solid organ transplantation is an established therapeutic approach in modern 
medicine to extend and to improve the life of patients in the final stages of organ 
failure. Transplantation between genetically non-identical individuals leads to 
the activation of the transplant recipient's immune system. This alloimmune 
response is a consequence of the recognition of foreign MHC molecules by 
alloreactive host T cells. To prevent their activation and the subsequently 
induced activation of further cell subsets (e.g. B cells, cytotoxic T cells, macro-
phages) immunosuppressive drugs are absolutely necessary in the clinic. How-
ever, permanent immunosuppression leads to severe side effects such as 
nephrotoxicity, diabetes and hyperlipidaemia, and a reduced immunity to infec-
tions and malignant diseases. At the moment, there is no real alternative to 
immunosuppression. 
 
The purpose of this study was to analyse the importance of rat dendritic cells 
with immune inhibitory properties to prevent the immune activation after 
experimental transplantation. The rat is one of the most important animal 
models for experimental organ transplantation in a clinic-relevant procedure. In 
order to modulate the immune response after transplantation in an antigen-
specific manner, the strategy should include the alloantigens. These antigens 
have to be presented by immature dendritic cells in the absence of co-
stimulatory signals in order to turn alloreactive T cells into anergic or regulatory 
T cells instead of effector T cells. For a certain rat model of allograft rejection, 
the immunodominant peptide P1 was identified as an important alloantigen 
which accelerates graft rejection. Such a model offers an attractive and practical 
approach to analyse the potential of host tolerogeneic dendritic cells pulsed with 
P1 to suppress the allograft-induced immune response in an antigen-specific 
manner without the need of chronic immunosuppression. 
 
A homogenous population of rat immature dendritic cells was generated from 
bone marrow precursors cultured with GM-CSF and IL-4 (= IL-4 DCs) or GM-
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CSF and IL-10 (= IL-10 DCs). These cells with an identical immature phenotype 
showed no or a very low surface expression of costimulatory molecules like 
CD80 and CD86 and a 10-fold reduced expression of MHC class II molecules in 
comparison to mature splenic DCs. No obvious difference was observed 
between the phenotype of the IL-4 DCs and the IL-10 DCs.  
 
Neither IL-4 DCs nor IL-10 DCs were able to activate naïve T cells or to 
restimulate antigen-specific T cells. This strong inhibitory effect, mediated within 
24 hours, was dependent on the number of immature dendritic cells added to 
the proliferation assay. Antigen-specific T cells pre-incubated with IL-4 DCs and 
IL-10 DCs, respectively, were not able to proliferate in the presence of P1-
pulsed mature DCs. This anergic state was reversible with the addition of 
exogenous IL-2. T cells incubated with IL-4 DCs (= IL-4 DC-Ts) were able to 
inhibit the T cell proliferation in a cell number dependent manner. In contrast, 
antigen-specific T cells pre-incubated with P1-pulsed IL-10 DCs (= IL-10 DC-Ts) 
showed no effect on the proliferation assay. This was the unique difference 
between IL-4 DCs and IL-10 DCs found in the present study. 
 
Immature DCs influenced also the immune response after transplantation. 
Different numbers of P1-loaded immature IL-4 DCs and IL-10 DCs were 
transferred intravenously into Lewis rats one day before transplantation. The 
best results were obtained with 30 million P1-pulsed immature DCs which 
prolonged the survival time to a median of 11.2 ± 1.6 days. In addition, the 
antigen specificity of this effect was demonstrated with a third-party graft from 
Brown Norway donors.  
 
These findings suggest that an antigen-specific modulation of the immune 
response is possible using immature dendritic cells loaded with the allogeneic 
antigens. Even more, the protocols described in the present study show that the 
immune system can be, at least temporarily, controlled after transplantation 
without the use of immunosuppressive drugs. 
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8 Zusammenfassung 
 
Die allogene Organtransplantation, d.h. die Übertragung zwischen genetisch 
nicht-identischen Individuen der gleichen Spezies, ist bei irreversiblen Organ-
erkrankungen nach wie vor die Therapie der Wahl. Die Transplantatabstoßung 
ist eine zum Funktionsverlust von Organtransplantaten führende T-Zell-
vermittelte Immunantwort. Ihre Ursache liegt in der Inkompatibilität von Organ-
transplantat und Transplantat-Empfänger hinsichtlich der Moleküle des Haupt-
histokompatibilitätskomplexes, die auch als Alloantigene bezeichnet werden. 
Zwar lässt sich die Transplantatabstoßung mit immunsuppressiven Medikamen-
ten hemmen, doch vermindern diese die Immunabwehr und begünstigen die 
Entstehung von Infektionen und Tumorerkrankungen. Für die klinische Trans-
plantation gibt es momentan keine Alternativen zur Immunsuppression.  
 
Um das Transplantat ohne Immunsuppression dauerhaft zu schützen, müssen 
die regulatorischen Komponenten des Immunsystems gezielt gestärkt werden. 
Das Ziel dieser Arbeit war es deshalb, die inhibierende Wirksamkeit unreifer 
dendritischer Zellen auf die nach Transplantation einsetzende Alloimmunant-
wort zu überprüfen.  
 
Charakteristisch für die Alloimmunantwort ist die Vielzahl der beteiligten 
Alloantigene. Doch ist es in den letzten Jahren gelungen, Peptidantigene mit 
einer nachweisbaren Funktion bei der Transplantatabstoßung (vermittelt über 
den indirekten Weg der Alloantigenerkennung) zu identifizieren. Für die in 
dieser Arbeit verwendete experimentelle Spender-Empfänger-Kombination ist 
die Bedeutung des Alloantigens P1, hierbei handelt es sich um ein aus 19 
Aminosäuren bestehendes Peptid, für die Alloimmunantwort bekannt.  
 
Autologe unreife dendritische Zellen lassen sich aus Knochenmarkvorläufer-
zellen mit GM-CSF und IL-4 (diese Zellen werden als IL-4 DCs bezeichnet) 
bzw. mit GM-CSF und IL-10 (IL-10 DCs) kultivieren. Sowohl für IL-4 DCs als 
auch IL-10 DCs wurde keine bzw. eine sehr geringe Expression der kostimula-
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torischen Moleküle CD80 und CD86 auf ihrer Zelloberfläche nachgewiesen. Die 
Oberflächenexpression von MHC-Klasse II Molekülen war im Vergleich zu 
reifen, aus der Milz isolierten dendritischen Zellen, um den Faktor 10 reduziert.  
 
In einem nächsten Schritt wurde die Wirkung von IL-4 DCs und IL-10 DCs auf 
T-Lymphozyten getestet. Sie können weder naive T-Lymphozyten aktivieren 
noch antigenspezifische T-Lymphozyten restimulieren. Der von diesen Zellen 
vermittelte suppressive Effekt wurde innerhalb von 24 Stunden wirksam und 
war eindeutig abhängig von der Zellzahl. Antigenspezifische T-Lymphozyten 
waren nach ihrer Inkubation mit IL-4 DCs oder IL-10 DCs nicht mehr mit P1-
beladenen reifen DCs zu restimulieren. Dieser anergische Zustand ließ sich 
aber nach Zugabe von IL-2 aufheben. Anergische T-Lymphozyten, die mit IL-4 
DCs kokultiviert wurden (= IL-4 DC-Ts), zeigten ihrerseits einen inhibierenden 
Effekt auf antigenspezifische T-Lymphozyten. Im Gegensatz dazu waren IL-10 
DC-Ts hierzu nicht in der Lage. Dies ist der einzige Unterschied zwischen IL-4 
DCs und IL-10 DCs, der in dieser Arbeit gefunden wurde. 
 
Auch in vivo zeigten IL-4 DCs und IL-10 DCs sowohl eine inhibierende Wirkung 
auf die lokale T-Zellpopulation als auch einen protektiven Effekt auf die 
Transplantatfunktion. Diese ließ sich in Abhängigkeit von der Zellzahl um 4 
Tage ohne jegliche Unterstützung mit Immunsuppressiva verlängern. Dabei 
wurden maximal 30 Millionen unreife DCs pro Lewis Ratte eingesetzt, was ca. 
10 Millionen Zellen pro 100 g Körpergewicht entspricht. Ihr immunprotektiver 
Effekt war dabei eindeutig antigenspezifisch.  
 
Insgesamt lassen die Ergebnisse den Schluss zu, dass autologe unreife 
dendritische Zellen, beladen mit Alloantigenen, eine hochattraktive Strategie zur 
antigenspezifischen Modulation der Alloimmunantwort nach Transplantation 
darstellen. In weiteren Studien soll die Effizienz dieser Zellen gesteigert werden.  
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rejection (C). In the syngeneic control group I the survival of syngeneic grafts was not 
influenced by P1 (D). The working hypothesis of this study is based on the assumption that P1-
loaded immature autologous dendritic cells (DC) inhibit specifically the allograft rejection (E). 
This possible effect of P1-loaded immature autologous DC should be analysed in vivo (F). The 
indefinite survival of syngeneic grafts (G) is not influenced by non-pulsed immature autologous 
DC (H). 
 
 
 
Commentaries: 
 
Figure 4.18 and 4.19: 
The strenght of the BM-DCs induced inhibition is different in Figure 4.18 and 
4.19. One explanation for this could be the different quality between the BM-
DCs recovered from the cultures at day 6. In later experiments we found that 
day 6 BM-DCs are expressing different levels of CD80 from very low up to a 
very strong expression.  
 
 Number of DCs Inhibition in % 
1x104 SDCs 1x104 IL-4 DCs 40% 
Figure 4.18 
1x104 SDCs 1x104 IL-10 DCs 63% 
1x104 SDCs 1x104 IL-4 DCs 
Figure 4.19 
1x104 SDCs 1x104 IL-10 DCs 
> 95% 
 
 
Chapter 4.7:  
The results shown on Figure 4.25 demonstrate that immature DCs are able to 
prime antigen-specific T cells in local lymph nodes. However, presently it is not 
clear wheather these antigen-specific T cells are effector or suppressor T cells. 
Therefore, the cytokine profile of these cells will be investigated. Both subsets 
of BM-DCs were able to prolong the allograft survival for few days in the 
transplantation model. This may indicate that the in vivo primed T cells are able 
to exert a suppressive effect.  
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Table 10.1: Summary of the transplantation experiments. The results clearly indicate an 
effect of IL-4 DCs and IL-10 DCs on the prolongation of allograft survival. For more information 
about the transplantation model see “Material and Methods” (Figure 3.1). 
 
Group Strain 
combination P1 
Day of 
Injection DC Route Date 
Day of 
Rejection 
1 Allogeneic Control 
      
HTX 01/04 WF → LEW – – – – 10.11.04 8 
HTX 02/04 WF → LEW – – – – 11.11.04 7 
HTX 01/05 WF → LEW – – – – 10.02.05 8 
HTX 02/05 WF → LEW – – – – 16.02.05 7 
HTX 18/05 WF → LEW – – – – 08.06.05 7 
HTX 19/05 WF → LEW – – – – 14.06.05 7 
        
2 Allogeneic Control + P1 
      
HTX 01/02 WF → LEW Yes -7 – s.c. 02.05.02 5 
HTX 02/02 WF → LEW Yes -7 – s.c. 02.05.02 5 
HTX 03/02 WF → LEW Yes -7 – s.c. 03.05.02 6 
HTX 05/04 WF → LEW Yes -7 – s.c. 24.11.04 5 
HTX 06/04 WF → LEW Yes -7 – s.c. 25.11.04 5 
        
3 Syngeneic Control 
      
HTX 02/02 LEW → LEW – – – – 09.02.02 > 50 
HTX 03/02 LEW → LEW – – – – 09.02.02 > 50 
HTX 11/04 LEW → LEW – – – – 13.12.04 > 50 
        
4 Syngeneic Control + P1 
      
HTX 01/02 LEW → LEW Yes -7 – s.c. 05.11.02 > 50 
HTX-N2/02 LEW → LEW Yes -7 – s.c. 05.11.02 > 50 
HTX 44/05 LEW → LEW Yes -7 – s.c. 24.11.05 > 50 
        
5 Control LEW DC (d -7, d -1) 
     
HTX 03/05 WF → LEW – -7 107 IL-4 DC i.v. 18.04.05 7 
HTX 04/05 WF → LEW – -7 107 IL-4 DC i.v. 20.04.05 7 
HTX 11/05 WF → LEW – -7 107 IL-4 DC i.v. 18.04.05 7 
HTX 12/05 WF → LEW – -7 107 IL-4 DC i.v. 20.04.05 7 
HTX 31/05 WF → LEW – -1 107 IL-4 DC i.v. 20.09.05 7 
HTX 32/05 WF → LEW – -1 107 IL-4 DC i.v. 20.09.05 6 
HTX 33/05 WF → LEW – -7 107 IL-4 DC i.v. 27.09.05 7 
HTX 34/05 WF → LEW – -7 107 IL-4 DC i.v. 27.09.05 8 
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Table 10.1 (continued): Summary of the transplantation experiments. 
        
Group Strain 
combination P1 
Day of 
Injection DC Route Date 
Day of  
Rejection 
6 LEW IL-4 DC + P1 (d -7) 
      
HTX 09/04 WF → LEW Yes -7 107 IL-4 DC i.v. 13.12.04 9 
HTX 05/05 WF → LEW Yes -7 107 IL-4 DC i.v. 03.05.05 8 
HTX 06/05 WF → LEW Yes -7 107 IL-4 DC i.v. 09.05.05 8 
HTX 07/05 WF → LEW Yes -7 107 IL-4 DC i.v. 10.05.05 7 
HTX 13/05 WF → LEW Yes -7 107 IL-4 DC i.v. 03.05.05 8 
HTX 14/05 WF → LEW Yes -7 107 IL-4 DC i.v. 09.05.05 8 
HTX 15/05 WF → LEW Yes -7 107 IL-4 DC i.v. 10.05.05 7 
 
      
7 LEW IL-10 DC + P1 (d -7) 
      
HTX 10/04 WF → LEW Yes -7 107 IL-10 DC i.v. 13.12.04 9 
HTX 08/05 WF → LEW Yes -7 107 IL-10 DC i.v. 11.05.05 9 
HTX 09/05 WF → LEW Yes -7 107 IL-10 DC i.v. 18.05.05 7 
HTX 16/05 WF → LEW  Yes -7 107 IL-10 DC i.v. 11.05.05 9 
HTX 17/05 WF → LEW Yes -7 107 IL-10 DC  i.v. 18.05.05 7 
        
8 LEW IL-4 DC + P1 (d -1) 
      
HTX 22/05 WF → LEW Yes -1 107 IL-4 DC i.v. 29.06.05 9 
HTX 23/05 WF → LEW Yes -1 107 IL-4 DC i.v. 30.06.05 11 
HTX 24/05 WF → LEW Yes -1 107 IL-4 DC i.v. 05.07.05 9 
HTX 30/05 WF → LEW Yes -1 107 IL-4 DC i.v. 04.08.05 9 
  
 
     
9 LEW IL-10 DC +P1 (d -1) 
      
HTX 20/05 WF → LEW Yes -1 107 IL-10 DC i.v. 15.06.05 9 
HTX 21/05 WF → LEW Yes -1 107 IL-10 DC i.v. 16.06.05 10 
HTX 25/05 WF → LEW Yes -1 107 IL-10 DC i.v. 08.07.05 10 
HTX 26/05 WF → LEW Yes -1 107 IL-10 DC i.v. 27.07.05 8 
HTX 27/05 WF → LEW Yes -1 107 IL-10 DC i.v. 27.07.05 10 
HTX 28/05 WF → LEW Yes -1 107 IL-10 DC i.v. 02.08.05 10 
HTX 29/05 WF → LEW Yes -1 107 IL-10 DC i.v. 02.08.05 9 
HTX 39/05 WF → LEW Yes -1 107 IL-10 DC i.v. 16.11.05 10 
        
10 Third-party (BN) Control 
      
HTX 37/05 BN → LEW – – – – 07.11.05 7 
HTX 38/05 BN → LEW – – – – 08.11.05 7 
HTX 41/05 BN → LEW – – – – 21.11.05 7 
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Table 10.1 (continued): Summary of the transplantation experiments. 
        
Group Strain 
combination P1 
Day of 
Injection DC Route Date 
Day of  
Rejection 
11 Third-party Control + LEW IL-10 DC + P1 
   
HTX 40/05 BN → LEW Yes -1 107 IL-10 DC i.v. 17.11.05 7 
HTX 42/05 BN → LEW Yes -1 107 IL-10 DC i.v. 22.11.05 7 
HTX 43/05 BN → LEW Yes -1 107 IL-10 DC i.v. 23.11.05 7 
        
12 LEW IL-10 DC + P1  (d -1) 
   
HTX 39/05 WF → LEW Yes -1 3x107 IL-10 DC i.v. 16.11.05 10 
HTX 46/05 WF → LEW Yes -1 3x107 IL-10 DC i.v. 08.12.05 12 
HTX 47/05 WF → LEW Yes -1 3x107 IL-10 DC i.v. 13.12.05 10 
HTX 49/06 WF → LEW Yes -1 3x107 IL-10 DC i.v. 24.01.06 12 
HTX 50/06 WF → LEW Yes -1 3x107 IL-10 DC i.v. 31.01.06 11 
HTX 51/06 WF → LEW Yes -1 3x107 IL-10 DC i.v. 01.02.06 10 
        
Experiments not shown in the results  
    
HTX 03/04 WF → LEW Yes -7 107 IL4-DC i.v. 17.11.04 8 
HTX 04/04 WF → LEW Yes -7 107 IL10-DC i.v. 17.11.04 8 
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Date 
 
13.04.05 
19.04.05 
19.04.05 
25.04.05 
25.04.05 
09.05.05 
25.05.05 
14.09.05 
13.04.05 
19.04.05 
25.04.05 
04.05.05 
09.05.05 
25.05.05 
07.06.05 
09.06.05 
13.07.05 
21.07.05 
 
 
OX18 
MHC-I 
– 
– 
– 
– 
– 
24 (2,3) 
8 (1,1) 
– 
– 
– 
– 
55 (3,4) 
57 (4,2) 
7 (1,5) 
– 
– 
– 
– 
 
 
Ox-42 
CD11b/c 
181 (17) 
– 
– 
98 (8,5) 
182 (13) 
106 (6,6) 
116 (15) 
– 
249 (50) 
– 
221 (15) 
188 (15) 
187 (16) 
153 (21) 
– 
– 
56 (7,7) 
– 
 
 
Ox-22 
CD45RC 
11 (17) 
– 
– 
– 
11 (13) 
– 
– 
– 
50 (26) 
– 
14 (15) 
– 
– 
– 
– 
– 
30,5 (7,7) 
– 
 
 
Ox-1 
CD45 
255 (17) 
– *
)
 
– 
196 (8,5) 
328 (13) 
278 (6,6) 
274 (15) 
– 
354 (50) 
– 
321 (15) 
323 (15) 
298 (16) 
212 (21) 
– 
– 
493 (7,7) 
– 
 
 
CTLA-4Ig 
CD80/86 
15 (9,7) 
7,8 (3,9) 
11 (3,9) 
11,7 (7,6) 
30 (10,5) 
10 (4,7) 
14 (11) 
11 (12,9) 
38 (15) 
29 (10,3) 
20 (9,6) 
16 (9) 
22 (9,3) 
24 (11) 
304 (220) 
260 (133) 
88 (28) 
89 (21) 
 
 
Ox-6 
MHC-II 
58 (3,6) 
24 (2,3) 
36 (3,4) 
22 (3,7) 
27 (4,5) 
24 (2,3) 
16 (1,1) 
32,2 (5,5) 
78 (6) 
100,6 (9) 
61 (6) 
53 (3,4) 
58 (4,2) 
15 (1,5) 
523 (5,1) 
113 (8,6) 
254 (3,5) 
460 (8,9) 
 
 
Antibodies 
Ox-62 
CD 103 
43 (9,7) 
25 (3,9) 
34 (3,9) 
33 (7,6) 
28 (10,5) 
29 (4,7) 
19 (11) 
21 (12,9) 
71 (15) 
59 (10,3) 
37 (9,6) 
40 (9) 
35 (9,3) 
20 (11) 
468 (220) 
274 (133) 
271 (28) 
164 (21) 
 
Table 10.2: IL-4 DCs and IL-10 DCs demonstrated an immature phenotype in comparison to mature S-DCs. The flow 
cytometric results represent the mean fluorescence intensity of different surface molecules. The background staining of isotype 
antibodies are in brackets. *) not measured: 
 
 
Cell Type 
 
IL-4 DC 
IL-4 DC 
IL-4 DC 
IL-4 DC 
IL-4 DC 
IL-4 DC 
IL-4 DC 
IL-4 DC 
IL-10 DC 
IL-10 DC 
IL-10 DC 
IL-10 DC 
IL-10 DC 
IL-10 DC 
S-DC 
S-DC 
S-DC 
S-DC 
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IL-10 
– 
– 
– 
+ 
+ 
+ 
+ 
+ 
– 
– 
– 
– 
+ 
+ 
+ 
+ 
– 
– 
– 
– 
– 
– 
– 
– 
+ 
 
IL-12 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
+ 
+ 
+ 
+/- 
+/- 
+ 
– 
– 
– 
– 
– 
+ 
 
IL-2 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
+ 
 
iNOS 
+ 
+ 
– 
– 
– 
– 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
– 
+ 
+ 
+ 
+ 
 
CD86 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
– 
+/- 
+ 
+ 
+ 
+ 
 
CD80 
+ 
+ 
+ 
+ 
– 
– 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
– 
+ 
+/- 
– 
– 
+ 
+ 
+ 
+ 
 
CD40 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
– 
– 
+ 
+ 
+ 
+ 
 
MHC II 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
– 
+ 
+ 
+ 
+ 
+ 
 
GAPDH 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
 
RT- PCR 
18.04.05 
18.04.05 
02.05.05 
02.05.05 
12.10.05 
12.10.05 
12.10.05 
12.10.05 
24.03.05 
24.03.05 
24.03.05 
24.03.05 
18.04.05 
02.05.05 
12.10.05 
12.10.05 
02.05.05 
20.06.05 
18.04.05 
20.06.05 
24.03.05 
24.03.05 
24.03.05 
24.03.05 
20.06.05 
 
RNA Isolation 
07.04.05 
07.04.05 
26.04.05 
26.04.05 
03.05.05 
03.05.05 
09.05.05 
09.05.05 
15.11.04 
03.12.05 
24.02.05 
22.03.05 
07.04.05 
26.04.05 
04.05.05 
09.05.05 
07.04.05 
07.04.05 
08.04.05 
13.04.05 
27.02.04 
17.08.05 
12.11.05 
13.01.05 
16.06.05 
 
Table 10.3: Qualitative RT-PCR analysis of different preparations of IL-4 DCs and IL-10 DCs in comparison to freshly 
isolated bone marrow cells (BM) and mature splenic DCs (S-DCs). As shown in Figure 4.11 specific mRNA for CD80 and 
CD86 was proved. (+) Signal; (–) No signal; (+/-) low signal 
Cell Type 
IL-4 DC 
IL-4 DC 
IL-4 DC 
IL-4 DC 
IL-4 DC 
IL-4 DC 
IL-4 DC 
IL-4 DC 
IL-10 DC 
IL-10 DC 
IL-10 DC 
IL-10 DC 
IL-10 DC 
IL-10 DC 
IL-10 DC 
IL-10 DC 
BM 
BM 
BM 
BM 
S-DC 
S-DC 
S-DC 
S-DC 
S-DC 
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Table 10.4: Different concentrations of IL-10 had no effect on the proliferation of antigen-
specific T cells.*) P1-specific T cells (P1-T) were tested in the proliferation assay in the 
presence of P1-loaded mature splenic DCs (P1-T + P1-S-DCs) and in the autostimulation assay 
in the presence of P1 (P1-T + P1). Antigen-specific T cells cultured alone (P1-T) were used as 
controls. As described in materials and methods the cells were cultured for three days and 
pulsed with 0.5 µCi/well [3H]-thymidine for the last 6 hours of culture. 
 Concentration of IL-10 (ng/ml) 
Culture conditions  ∅ 1600 800 400 200 100 
P1-T + P1-S-DCs 35.0 ± 2.3 *) 33.7 ± 2.5 31.0 ± 2.0 31.5 ± 3.6 32.0 ± 2.3 34.0 ± 2.3 
P1-T + P1 16.0 ± 3.0 35.0 ± 2.3 18.5 ± 2.5 20.0 ± 2.7 19.4 ± 2.3 18.8 ± 2.6 
P1-T 3.90 ± 1.0 3.50 ± 2.3 4.20 ± 2.1 3.80 ± 2.0 4.50 ± 1.2 3.30 ± 1.6 
*
) Results (mean ± standard deviation) of T-cell proliferation in cpm x 103.  
(∅) Without IL-10. 
 
 
 
Table 10.5: Different concentrations of IL-4 increased slightly the proliferation of antigen-
specific T cells.*) P1-specific T cells (P1-T) were tested in the proliferation assay in the 
presence of P1-loaded mature splenic DCs (P1-T + P1-S-DCs) and in the autostimulation assay 
in the presence of P1 (P1-T + P1). Antigen-specific T cells cultured alone (P1-T) were used as 
controls. As described in materials and methods the cells were cultured for three days and 
pulsed with 0.5 µCi/well [3H]-thymidine for the last 6 hours of culture. 
 Concentration of IL-4 (ng/ml) 
Culture conditions  ∅ 6.66 13.2 
P1-T + P1-S-DCs  23.0 ± 1.9 *)  24.0 ± 2.9  29.0 ± 1.9 
P1-T + P1  6.50 ± 1.7  8.80 ± 1.3  10.0 ± 2.1 
P1-T  2.40 ± 0.9  3.70 ± 0.6  5.20 ± 1.2 
*
) Results (mean ± standard deviation) of T-cell proliferation in cpm x 103.  
(∅) Without IL-4 
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Compensation 
FL1–2.4%FL2 
FL2-32.6%FL1 
FL2-0.0%FL3 
FL3-0.0%FL2 
– 
FL1-0.0%FL2 
FL2-65.3%FL1 
FL2-0.0%FL3 
FL3-0.0%FL2 
– 
FL1-0.8%FL2 
FL2-18.0%FL1 
FL2-0.0%FL3 
FL3-18.1%FL2 
– 
Mode 
Lin 
Lin 
Log 
Log 
Log 
Lin 
Lin 
Log 
Log 
Log 
Lin 
Lin 
Log 
Log 
Log 
Amp. gain 
1.00 
1.00 
1.00 
1.00 
1.00 
5.73 
1.00 
1.00 
1.00 
1.00 
1.00 
1.00 
1.00 
1.00 
1.00 
Voltage 
E00 
316 
469 
469 
628 
E-1 
294 
416 
482 
628 
E00 
368 
654 
631 
782 
Detector 
FSC 
SSC 
FL1 
FL2 
FL3 
FSC 
SSC 
FL1 
FL2 
FL3 
FSC 
SSC 
FL1 
FL2 
FL3 
Table 10.6: The settings used for FACS analysis. The analysed cell types were BM-DCs (IL-4 DCs and 
IL-10 DCs), S-DCs (isolated from spleen) and lymphocytes. Amp. gain: Amplifier gain 
Parameter 
BM-DCs 
P1 
P2 
P3 
P4 
P5 
S-DCs 
P1 
P2 
P3 
P4 
P5 
Lymphocytes 
P1 
P2 
P3 
P4 
P5 
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